Exhibit 4.15


 





CONFIDENTIAL TREATMENT REQUESTED


 


THE
PORTIONS OF THIS AGREEMENT MARKED WITH ASTERISKS WITHIN BRACKETS (“[***]”) HAVE BEEN OMITTED PURSUANT TO A REQUEST
FOR CONFIDENTIAL TREATMENT UNDER 17 C.F.R. SECTIONS 200.80(B)(4), 200.83 AND 230.406.
A COMPLETE COPY OF THIS AGREEMENT HAS BEEN FILED SEPARATELY WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION.


 


Execution Version


 


MEMBERSHIP INTEREST PURCHASE AGREEMENT


 


by and among


 


ÉCLAT HOLDINGS, LLC, 


a Delaware limited liability company;


 


ÉCLAT PHARMACEUTICALS, LLC, 


a Delaware limited liability company;


 


FLAMEL TECHNOLOGIES SA, a société
anonyme organized under the laws of the Republic of France and


 


FLAMEL US HOLDINGS, INC., 


a Delaware corporation;


 


Dated as of March 13, 2012


 




    	[Confidential Treatment Requested]



    	 



    

 


TABLE OF CONTENTS 


 





	 	 	Page
	 	 	 
	1.     DESCRIPTION
    OF TRANSACTION	1
	 	 	 
	1.1	Purchase and Sale.	1
	1.2	Consideration.	1
	1.3	Closing Balance Sheet and Adjusted Working Capital Statement.	2
	1.4	Post-Closing Payments.	3
	1.5	Indebtedness.	3
	1.6	Closing; Effective Time; Closing Deliveries.	3
	1.7	Deferred Consideration.	4
	1.8	Warrant Valuation.	8
	1.9	FSC Agreement.	8
	 	 	 
	2.     REPRESENTATIONS
    AND WARRANTIES OF THE COMPANY	8
	 	 	 
	2.1	Organization; Good Standing.	8
	2.2	Consents and Approvals; No Violation.	8
	2.3	 Capital Stock; Subsidiaries.	9
	2.4	Financial Statements. Schedule 2.4	9
	2.5	Absence of Changes.	10
	2.6	Tax Matters.	11
	2.7	Claims.	12
	2.8	Compliance with Laws.	12
	2.9	Employee and Labor Matters; Benefit Plans.	12
	2.10	 Insurance.	13
	2.11	Real Property. Schedule 2.11	13
	2.12	Bank Accounts. Schedule 2.12	13
	2.13	Regulatory Compliance.	13
	2.14	Accounts Receivable.	14
	2.15	Proprietary Rights.	14
	2.16	Supply Arrangement. Schedule 2.17	15
	2.17	Contracts.	15
	2.18	Title to Assets.	16
	2.19	Necessary Assets.	16
	2.20	No State Antitakeover Statute.	16
	2.21	Brokers.	16
	2.22	Transaction Payments.	17
	2.23	No Other Representations or Warranties.	17
	 	 	 
	3.     REPRESENTATIONS
    AND WARRANTIES OF THE SELLER	17
	 	 	 
	3.1	Organization; Good Standing.	17
	3.2	Authority; Enforceability.	17
	3.3	Consents and Approvals; No Violation.	18
	3.4	No Other Representations or Warranties.	18




 




    	[Confidential Treatment Requested]



    	 



    

 


TABLE OF CONTENTS


(continued)


 





	 	 	Page
	 	 	 
	4.     REPRESENTATIONS
    AND WARRANTIES OF THE BUYER	18
	 	 	 
	4.1	Organization; Good Standing.	18
	4.2	Authority; Enforceability.	18
	4.3	Consents and Approvals; No Violation.	19
	4.4	No Restrictions.	19
	4.5	No Other Representations or Warranties.	19
	 	 	 
	5.
        ADDITIONAL AGREEMENTS OF THE PARTIES	19
	 	 
	5.1 Indemnification of Officers and Directors.	19
	5.2 Disclosure.	20
	5.3 Maintenance of Books and Records.	20
	5.4 Taxes.	20
	5.5 Eclat Name.	22
	 	 	 
	6.     INDEMNIFICATION	22
	 	 	 
	6.1	Survival.	22
	6.2	Seller Indemnification.	22
	6.3	Buyer Indemnification.	23
	6.4	Limitations.	23
	6.5	Procedure for Indemnification – Third-Party Claims.	24
	6.6	Right of Set-Off.	25
	6.7	Exclusive Remedy.	25
	 	 	 
	7.     MISCELLANEOUS
    PROVISIONS	25
	 	 	 
	7.1	Amendment.	25
	7.2	Waiver.	25
	7.3 Entire Agreement; Counterparts; Exchanges by Facsimile.	26
	7.4 Applicable Law; Jurisdiction.	26
	7.5 Assignability; No Third Party Beneficiaries.	27
	7.6 Notices.	27
	7.7	Severability.	28
	7.8	Other Remedies; Specific Performance.	28
	7.9	Noncompete.	28
	7.10	Judgment Currency.	29
	7.11	Construction.	29




 


Exhibits


 


	Exhibit A	Capitalized Terms 
	Exhibit B	Loan Agreement and Note 
	Exhibit C	Warrant Agreement 
	Exhibit D	Registration Rights Agreement 
	Exhibit E	Security Agreement 
	Exhibit F	Guaranty of Flamel 
	Exhibit G	Guaranty of Company 


 




    	[Confidential Treatment Requested]



ii



    	 



    

 


MEMBERSHIP INTEREST PURCHASE AGREEMENT 


 


THIS MEMBERSHIP INTEREST PURCHASE AGREEMENT
(this “Agreement”) is made and entered into as of March 13, 2012, by and among ÉCLAT HOLDINGS,
LLC, a Delaware limited liability company (the “Seller”), ÉCLAT PHARMACEUTICALS, LLC,
a Delaware limited liability company (the “Company”), FLAMEL US HOLDINGS, INC., a Delaware corporation
(the “Buyer”) and FLAMEL TECHNOLOGIES SA, a société anonyme organized under the
laws of the Republic of France (“Flamel”). Certain capitalized terms used in this Agreement are defined
in Exhibit A.


 


RECITALS 


 


The Seller desires to sell, and the Buyer desires
to purchase, all of the issued and outstanding membership interests of the Company, consisting of 10,000 Units (the “Units”),
for the consideration and on the terms set forth herein.


 


AGREEMENT 


 


The Parties to this Agreement, intending to be legally
bound, agree as follows:


 


1.             DESCRIPTION
OF TRANSACTION


 


1.1           Purchase
and Sale.


 


On the terms and subject to the conditions of this Agreement, effective
at the Effective Time, Seller shall sell and deliver to the Buyer, and the Buyer shall purchase and accept from Seller, all of
the Units, free and clear of all Encumbrances, in exchange for the consideration set forth herein.


 


1.2           Consideration.


 


In consideration of the sale of the Units, the Buyer shall pay
and/or issue, as applicable, to the Seller the Note and the Warrant Consideration at Closing and shall pay the Deferred Consideration
in accordance with Section 1.7.


(a)          The
“Note” shall be a secured promissory note issued by the Buyer in favor of the Seller at Closing pursuant to
the Note Agreement attached hereto as Exhibit B (the “Loan Agreement”) with a principal
amount equal to $12,000,000.


 


(b)          The
“Warrant Consideration” shall consist of issuance of the Warrant Agreements (the “Warrant Agreement”)
attached hereto as Exhibit C by Flamel which Flamel shall contribute to the Buyer and the Buyer shall immediately
transfer to the Seller at Closing. As promptly as practicable after Closing, but not later than September 30, 2012, Flamel shall
convene a meeting of the holders of its Ordinary Shares in accordance with French law and Flamel’s organizational documents
for the purpose of voting on the approvals set forth in the definition of “Shareholder Approval Date” in the Warrant
Agreement. Flamel and its Board of Directors shall recommend that holders of its Ordinary Shares approve the items set forth in
the definition of “Shareholder Approval Date” in the Warrant Agreement at any meeting held with respect to such approval.
For the avoidance of doubt, nothing in this Section 1.2(b) shall be construed to modify the definition of “Shareholder
Approval Date” under the Warrant Agreement.


 




    	[Confidential Treatment Requested]

1



    	 



    

  


1.3           Closing
Balance Sheet and Adjusted Working Capital Statement.


 


(a)          Schedule
1.3(a) sets forth an agreed estimate of the Adjusted Working Capital, which amount shall be equal to at least $2,000,000 (the
“Estimated Adjusted Working Capital”).


(b)          Within
60 days after the Closing, the Buyer will prepare and deliver to Seller (i) a consolidated balance sheet (the “Closing
Balance Sheet”) of the Company as of the Effective Time, prepared in accordance with GAAP, applied consistently in the
same manner as the Financial Statements (including the methodologies for calculating reserves) and (ii) a statement setting forth
in reasonable detail the actual Adjusted Working Capital as of the Effective Time based on the Closing Balance Sheet (the “Adjusted
Working Capital Statement”).


 


(c)          The
Seller shall have the right to review the work papers of the Buyer used in preparing the Closing Balance Sheet, and shall have
reasonable access to the books and records of the Company for purposes of verifying the accuracy and fairness of the presentation
of the Closing Balance Sheet and the Adjusted Working Capital Statement; provided, that such access shall be in a manner that
does not interfere with the normal business operations of the Buyer.


 


(d)          If
the Seller does not accept the Closing Balance Sheet or the Adjusted Working Capital Statement, the Seller shall give written
notice to the Buyer within 30 days after delivery thereof that sets forth in reasonable detail the basis and the purported amount
for each objection (the “Working Capital Objection Notice”). If the Seller does not provide such Working
Capital Objection Notice within such 30-day period, the Seller shall be deemed to have accepted the Closing Balance Sheet and
the Adjusted Working Capital Statement.


 


(e)          The
Buyer and the Seller shall use reasonable commercial efforts in good faith to resolve any objections raised in the Working Capital
Objection Notice for 30 days. If the Buyer and the Seller are unable to resolve any disagreement within 30 days after delivery
of the Working Capital Objection Notice, the parties will engage Grant Thornton (the “Reviewing Accountant”)
to resolve the issues in dispute. The Reviewing Accountant will apply accounting principles, in accordance with the provisions
of this Agreement, to the issues at hand and will not have the power to alter, modify, amend, add to or subtract from any term
or provision of this Agreement, and the Reviewing Accountant’s engagement will be limited in scope to the disputed issues
and amounts identified in the Working Capital Objection Notice. The parties will instruct the Reviewing Accountant to elect the
position of either the Buyer or the Seller as a resolution for each item of disagreement, not to impose an alternative resolution
with respect to any item of disagreement, to make its determination based solely on presentations and supporting material provided
by the Parties and not pursuant to any independent review and to render its decision within 30 days of the engagement. The fees,
costs and expenses of the Reviewing Accountant will be paid by the Seller and by the Buyer in the same proportion that the aggregate
amount of the disputed items submitted to the Reviewing Accountant that are unsuccessfully disputed by such party, as finally
determined by the Reviewing Accountant, bears to the amount of such disputed items so submitted. The determination of the Reviewing
Accountant will be final and binding on the Parties.


 




    	[Confidential Treatment Requested]

2



    	 



    

  


1.4           Post-Closing
Payments.


 


Within five Business Days after the Closing
Balance Sheet is deemed final pursuant to Section 1.3, (i) if the actual Adjusted Working Capital exceeds $2,000,000, then Buyer
shall pay to Seller the amount of such excess in cash, and (ii) if the actual Adjusted Working Capital is less than $2,000,000,
then the Seller shall pay the Buyer the amount of such deficiency in cash.


 


1.5           Indebtedness.


 


Immediately prior to the Closing, the current
lenders of the Company Indebtedness shall contribute all rights, title and interest constituting or related to the Company Indebtedness
to the Seller as capital contributions, and the Seller shall further contribute all such rights title and interest to the Company,
with the effect that at Closing there shall be no Company Indebtedness, all documents related to the Company Indebtedness are
terminated and all liens thereunder are released (the “Company Indebtedness Termination”).


 


1.6           Closing;
Effective Time; Closing Deliveries.


 


(a)         Closing;
Effective Time. The consummation of the transactions contemplated by this Agreement (the “Closing”)
shall take place remotely by the electronic or other exchange of documents and signature pages, on the date hereof, such date
referred to herein as the “Closing Date”. The Closing will be effective as of 12:01 a.m. on the Closing
Date (the “Effective Time”), and all actions scheduled in this Agreement to take place at the Closing
shall be deemed to occur simultaneously at such time.


 


(b)         Closing
Documents Delivered to the Sellers. At or prior to the Closing, the Seller shall have received:


 


(i)          The
Loan Agreement and the Note executed and delivered by the Buyer;


 


(ii)         The
Warrant Agreement executed and issued by Flamel evidencing the Warrant Consideration;


 


(iii)        The
Registration Rights Agreement, attached hereto as Exhibit D, executed and delivered Flamel;


 


(iv)        The
Security Agreement (the “Security Agreement”), attached hereto as Exhibit E, executed
and delivered by the Company;


 


(v)         The
Guaranty attached hereto as Exhibit F, executed and delivered by Flamel (the “Flamel Guaranty”);
and


 


(vi)        The
Guaranty attached hereto as Exhibit G, executed and delivered by the Company (the “Company Guaranty”).


 


 


(c)         Closing
Documents Delivered to the Buyer. At or prior to the Closing, the Buyer shall have received:


 




    	[Confidential Treatment Requested]

3



    	 



    

  


(i)          Resignation
letters, in form and substance reasonably acceptable to Buyer, of each of the managers and certain officers specified by the Buyer
of the Company Parties, effective as of the Effective Time;


 


(ii)         A
certificate executed by the Secretary of the Seller certifying that (A) attached thereto is a true and complete copy of the Seller’s
certificate of formation and all amendments thereto and then in effect, certified by the Secretary of State of the State of Delaware;
(B) attached thereto is a certificate of good standing of the Seller from the Secretary of State of the State of Delaware, dated
not more than five days before the Closing Date; (C) attached thereto is a true and complete copy of the Seller’s limited
liability company agreement and all amendments thereto and then in effect; (D) attached thereto is a true and complete copy of
the resolutions adopted by the members and managers of the Seller authorizing the execution, delivery and performance of the Agreement
and transactions contemplated hereby; and (E) as to the incumbency and signatures of each individual who will execute documents
at the Closing on behalf of the Seller;


 


(iii)        A
certificate executed by the Secretary of the Company certifying that (A) attached thereto is a true and complete copy of the Company’s
certificate of formation and all amendments thereto and then in effect, certified by the Secretary of State of the State of Delaware;
(B) attached thereto are certificates of good standing of the Company from its jurisdiction of organization and in each jurisdiction
in which it is licensed or qualified to conduct business; dated not more than five days before the Closing Date; (C) attached
thereto is a true and complete copy of the Company’s limited liability company agreement and all amendments thereto and
then in effect; (D) attached thereto is a true and complete copy of the resolutions adopted by the members and managers of the
Company authorizing the execution, delivery and performance of the Agreement and transactions contemplated hereby, and (E) as
to the incumbency and signatures of each individual who will execute documents at the Closing on behalf of the Company;


 


(iv)        Documentation
from the Company evidencing the Company Indebtedness Termination which provides that (A) after giving effect to the contributions
set forth in Section 1.5, (1) all agreements related to the Company Indebtedness are terminated, (2) all obligations related
to the Company Indebtedness are deemed paid in full, and (3) all liens related to the Company Indebtedness are released and (B)
the Seller and the Company authorize the Buyer to file any UCC termination statements deemed appropriate by the Buyer to effect
the Company Indebtedness Termination; and


 


(v)         Documentation
from FSC Laboratories acknowledging receipt and payment in full of all amounts due by the Company under the FSC Agreement.


 


1.7           Deferred
Consideration.


 


(a)          Deferred
Payments. The Buyer shall pay (or cause to be paid) to the Seller (or its successors and assigns) quarterly deferred payments
(each, a “Launch Products Deferred Payment”) equal to 20.0% of Launch Products Gross Profit for such
quarter (collectively, the “Launch Products Deferred Consideration”). The Buyer shall pay (or cause
to be paid) to the Seller (or its successors and assigns) quarterly deferred payments (each, a “Hycet Deferred Payment”)
equal to 100.0% of Hycet Gross Profit for such quarter (collectively, the “Hycet Deferred Consideration”),
up to a maximum of $1,000,000.


 




    	[Confidential Treatment Requested]

4



    	 



    

 


(b)          Payment
of the Deferred Payments. The Launch Products Deferred Payments described in Section 1.7(a) shall accrue daily and
shall be paid quarterly in arrears for each quarter from and after the Closing. The Hycet Deferred Payments described in Section
1.7(a) shall accrue daily and shall be paid quarterly in arrears for each quarter from and after the Closing until $1,000,000
in the aggregate of Hycet Deferred Payments have been paid to the Seller. No later than two Business Days following the date Flamel
files its Earnings Report (if a public filing) or has prepared its Earnings Report (if not a public filing) for each calendar
quarter (but in no event later than sixty days following the last day of each of the first three quarters and one hundred twenty
days following the last day of the fourth quarter of each calendar year), the Buyer shall pay to the Seller the Launch Products
Deferred Payment and Hycet Deferred Payment, as applicable, for such quarter. On the same day it makes a Launch Products Deferred
Payment or Hycet Deferred Payment pursuant to this Section 1.7(b), the Buyer shall deliver or cause to be delivered to
the Seller a written statement showing all Net Sales of Product and Net Sales of Launch Products, as applicable, during such quarter
and the Buyer’s computation of such Launch Products Gross Profit and Hycet Gross Profit, as applicable, and the corresponding
Launch Products Deferred Payment and Hycet Deferred Payment, as applicable (each a “Deferred Payment Calculation”).
All Launch Products Deferred Payments and Hycet Deferred Payments shall be made by wire transfer of immediately available funds
to the account(s) designated in writing by the Seller no later than five Business Days prior to the date such Launch Products
Deferred Payment and Hycet Deferred Payment shall be due.


 


(c)          Delinquent
Deferred Payments. Any Launch Products Deferred Payment or Hycet Deferred Payment not paid when due shall bear interest at
the Default Rate, compounded daily, or the highest rate then permitted by applicable law, whichever is less.


 


(d)          Audit
Right. Upon not less than ten Business Days written notice (the “Audit Notice”), the Seller shall
have the right to audit the books and records of the Buyer and the Company Parties for the purpose of determining the correctness
of their computation and payment of any Launch Products Deferred Payment and/or Hycet Deferred Payment for up to three years prior
to the date of the Audit Notice and for the purposes of determining compliance with the other covenants set forth in this Section
1.7. Such audit may not be conducted more than once in any calendar year and shall be conducted during normal business hours
at the Seller’s cost, provided, that any accounting firm or other Representative involved enters into a reasonable confidentiality
agreement with the Company (to be approved by the Company in its sole reasonable discretion) prior to commencing any such audit.
The Buyer shall provide the Seller and its advisors with reasonable access to all pertinent books and records of the Company related
to the Product or the Launch Products and shall reasonably cooperate with the Seller’s and its advisors’ efforts to
conduct such audits. The Seller may object to any Deferred Payment Calculation by delivering a written notice of objection (a
“Deferred Payment Calculation Objection Notice”), which shall specify the items in the applicable Deferred
Payment Calculation disputed by Seller and shall describe in reasonable detail the basis for such objection, as well as the amount
in dispute. If Seller delivers a Deferred Payment Calculation Objection Notice, Buyer and Seller shall negotiate in good faith
for up to ten Business Days to resolve the disputed items and agree upon the resulting amount of the Launch Products Deferred
Payment and/or Hycet Deferred Payment that is the subject of the Deferred Payment Calculation Objection Notice. If Buyer and Seller
are unable to reach agreement within ten Business Days after the Deferred Payment Calculation Objection Notice has been delivered,
all unresolved disputed items shall be promptly referred to the Reviewing Accountant. The Reviewing Accountant shall be directed
to render a written report on the unresolved disputed items with respect to the applicable Deferred Payment Calculation as promptly
as practicable, but in no event greater than 30 days after such submission to the Reviewing Accountant, and to resolve only those
unresolved disputed items set forth in the Deferred Payment Calculation Objection Notice. If unresolved disputed items are submitted
to the Reviewing Accountant, Buyer and Seller shall each furnish to the Reviewing Accountant such work papers, schedules and other
documents and information relating to the unresolved disputed items as the Reviewing Accountant may reasonably request. The Reviewing
Accountant shall resolve the disputed items based solely on the applicable definitions and other terms in this Agreement and the
presentations by Buyer and Seller, and not by independent review. The Reviewing Accountant will not have the power to alter, modify,
amend, add to or subtract from any term or provision of this Agreement. The resolution of the dispute and the calculation of the
Launch Products Deferred Payment and/or Hycet Deferred Payment that is the subject of the Deferred Payment Calculation Objection
Notice by the Reviewing Accountant shall be final and binding on the parties hereto. If there has been an underpayment of the
aggregate Launch Products Deferred Payment and/or Hycet Deferred Payment due for the period being audited of more than five percent
(5%) of the amount due for the period, the Buyer shall reimburse the Seller for the reasonable out-of pocket costs (including
Reviewing Accountants’ fees) incurred by the Seller pursuant to this Section 1.7(d).


 




    	[Confidential Treatment Requested]

5



    	 



    

 


(e)          Assignment
or Sublicense by the Buyer. The Buyer shall continue to be obligated to pay the Launch Products Deferred Payments and Hycet
Deferred Payments on all sales by all direct or indirect licensees and assignees of any rights to sell, market or otherwise distribute
the Product and/or the Launch Products, and the provisions of this Section 1.7 shall apply to all such sales as if made
directly by the Buyer.


 


(f)          Covenants
of the Buyer.


 


(i)          Regulatory
Approvals. The Company shall use all commercially reasonable efforts to obtain approval of each NDA necessary to sell each
Launch Product in the United States of America. Without limiting the foregoing, the Company shall (A) initiate development and
manufacturing of all Launch Products through a third-party (if this has not already occurred as of Closing) and (B) pursue a pre-IND/pre-NDA
meeting with the FDA for each of the Launch Products (if this has not already occurred as of Closing). The Company shall also
use commercially reasonable efforts to (x) cause registration batches of each Launch Product to be manufactured and (y) cause
stability testing to be completed for each Launch Product, in each case unless the FDA states in the pre-IND/pre-NDA meeting
applicable to such Launch Product that such Launch Product would not be approved without clinical trials or other unexpected conditions
to approval that would make continued efforts to obtain the NDA necessary for commercialization of the Launch Product not commercially
viable.


 


(ii)         Marketing
of Launch Products. Upon approval to market any Launch Product, the Company shall take all commercially reasonable and appropriate
actions to manufacture or have manufactured, package, label, distribute, offer for sale and sell such Launch Product. The Company
shall take all commercially reasonable and appropriate actions to manufacture or have manufactured, package, label, distribute,
offer for sale and sell Product for so long as it has an obligation to pay any Hycet Deferred Payment.


 




    	[Confidential Treatment Requested]

6



    	 



    

 


(iii)        Credit
Facility Restrictions. The Buyer and Flamel each represents and warrants that there are no restrictions or limitations on
Buyer’s ability to make the payments that are or may be required to be paid to the Seller under this Agreement (directly
or pursuant to the Flamel Guaranty or the Company Guaranty, as applicable) in any Contract of Flamel, the Buyer or the Buyer’s
Subsidiaries (including in any loan agreement, note debenture or other document evidencing any indebtedness of Flamel, the Buyer
and its Subsidiaries). Flamel shall not enter into, or amend, any Contract of it or its Subsidiaries after the Closing the effect
of which is to place any restrictions or limitations on Flamel’s or the Company Parties’ ability to make the payments
that are or may be required to be paid to the Seller under this Agreement (directly or pursuant to the Flamel Guaranty or the
Company Guaranty, as applicable); provided, however, that the foregoing restriction shall not apply to (i) up to €15,000,000
of indebtedness of Flamel or its Subsidiaries owed to the French government (or one of its instrumentalities or agencies) or (ii)
indebtedness incurred by Flamel or its Subsidiaries the proceeds of which are used to make any payments due under the Warrant
Agreement.


 


(iv)        No
Transfer Without Consent. The Company shall not transfer (whether by sale, assignment, merger, change of control, conveyance
of rights, deed of trust, lien, license, sublicense, seizure or other transfer of any sort, voluntary or involuntary, including
by operation of law) any of its right, title or interest in or to the Product Intellectual Property or Product Regulatory Rights
unless the assignee/transferee agrees in writing to assume (in addition to the Buyer and the Company) all of the Buyer’s
and the Company’s obligations under this Agreement; provided, however, such requirement shall not apply to
(i) the direct or indirect license of Product Intellectual Property or Product Regulatory Rights to make, have made, use, promote,
import, offer to sell or sell Product and/or Launch Products solely on behalf of, or for the benefit of, the Company or (ii) the
direct or indirect license of Product Intellectual Property or Product Regulatory Rights for any reason other than to make, have
made, use, promote, import, offer to sell or sell Product and/or Launch Products.


 


(g)          Acceleration.
Notwithstanding anything to the contrary contained in this Section 1.7 (including, without limitation, the quarterly structuring
of deferred payments set forth above), upon and at any time after the occurrence of any Acceleration Trigger Event, (x) an amount
equal to the Accelerated Earn-Out Value (together with any applicable interest accrued thereon) shall automatically become immediately
due and payable without presentment, demand, protest, notice of intent to accelerate or other notice or legal process of any kind,
all of which are hereby knowingly and expressly waived by the Buyer, and (y) the Seller may exercise any and all other rights
and remedies available to it under this Agreement and applicable law. At least once per year, the Buyer will update in good faith
its sales projections for the Product and the Launch Products.


 


(h)          No
Security. The parties hereto understand and agree that (i) the contingent rights to receive any Launch Products Deferred
Payment and Hycet Deferred Payment shall not be represented by any form of certificate or other instrument and do not constitute
an equity or ownership interest in Buyer or the Company, (ii) Seller shall not have any rights as a securityholder of Buyer or
the Company as a result of Seller's contingent right to receive any Launch Products Deferred Payment and Hycet Deferred Payment
hereunder, and (iii) no interest is payable with respect to any Launch Products Deferred Payment and Hycet Deferred Payment except
as provided in Section 1.7(c).


 


(i)          Security
Interest. The Parties hereby acknowledge the grant of a security interest by Eclat Pharmaceuticals, LLC in the collateral
set forth in the Security Agreement to secure the payment of the Launch Products Deferred Payments and Hycet Deferred Payments.


 




    	[Confidential Treatment Requested]

7



    	 



    

  


1.8           Warrant
Valuation.


 


The Buyer and the Seller agree that the value
of the Warrant Consideration is set forth in Schedule 1.8.


 


1.9           FSC
Agreement.


 


Immediately prior to the Effective Time, the
Company shall pay all amounts due to FSC under the FSC Agreement, and the cash used to make such payment shall for purposes of
clarification not be included in Adjusted Working Capital.


 


2.          REPRESENTATIONS
AND WARRANTIES OF THE COMPANY


 


Each Company Party represents and warrants
to the Buyer as set forth below, except as set forth in the written disclosure schedule delivered or made available by the Company
Parties to the Buyer (the “Disclosure Schedule”). The Disclosure Schedule shall be arranged in sections
and subsections corresponding to the numbered and lettered sections and subsections contained in this Agreement. The Disclosure
Schedule may include items that are not material in order to avoid any misunderstanding, and any such inclusion, or any references
to dollar amounts, shall not be deemed to be an acknowledgment or representation that such items are material, to establish any
standard of materiality or to define further the meaning of such terms for purposes of this Agreement. Any information or matter
disclosed on a Schedule shall be deemed to be disclosed on such Schedule and each other Schedule to the extent it is reasonably
apparent on the face of the disclosure that such disclosure is applicable to such other Schedule.


 


2.1           Organization;
Good Standing.


 


Each Company Party is duly organized, validly
existing and in good standing under the laws of the state of its formation. Each Company Party has the requisite power and authority
to own, lease or use its properties and assets and to conduct its business as presently conducted. Schedule 2.1 sets forth each
jurisdiction in which any Company Party is licensed or qualified to do business, and each Company Party is duly licensed or qualified
to do business and is in good standing in each jurisdiction in which the assets or properties owned or leased by it or the operation
of its business as currently conducted makes such licensing or qualification necessary. Schedule 2.1 lists all of the officers
and directors of each Company Party.


 


2.2           Consents
and Approvals; No Violation.


 


Except as disclosed in Schedule 2.2, neither
the execution and delivery of this Agreement by the Seller nor the performance of its obligations hereunder nor the consummation
by the Seller of the transactions contemplated hereby will: (i) conflict with or result in a breach, violation, or default of
or under the certificate of formation or other governing or organizational document of any Company Party, (ii) require the consent
of, or notice to, any Person under, conflict with, result in a violation or breach of, constitute a default or an event that,
with or without notice or lapse of time or both, would constitute a default under, result in the acceleration of or create in
any party the right to accelerate, terminate, modify or cancel any Contract to which Seller or any Company Party is a party or
by which Seller or any Company Party is bound or to which any of their respective properties and assets are subject (including
any Contract) or any Governmental Authorization affecting the properties, assets or business of the Company Parties, (iii) result
in the creation of any Encumbrance (other than Permitted Encumbrances) on the assets or Equity Interests of any Company Party,
or (iv) conflict with or result in a violation or breach of any provision of any Legal Requirement applicable to the Seller or
the Company Parties.


 




    	[Confidential Treatment Requested]

8



    	 



    

 


2.3           
Capital Stock; Subsidiaries.


 


(a)          The
issued and outstanding membership interests of the Company consist of 10,000 Units. The Units transferred to the Buyer pursuant
to this Agreement represent 100% of the issued and outstanding Equity Interests of the Company. The Seller is the sole record
and beneficial owner and holder, free and clear of all Encumbrances, of all of the Units, and upon consummation of the transactions
contemplated by this Agreement, Buyer shall own all the Units, free and clear of all Encumbrances except those created by Buyer.
All of the Units were issued in compliance with all applicable Legal Requirements. None of the Units were issued in violation
of any agreement, arrangement or commitment to which Seller or any Company Party is a party or is subject to or in violation of
any preemptive or similar rights of any Person. There are no outstanding warrants, options, agreements, convertible or exchangeable
securities or other agreements, arrangements or commitments of any character pursuant to which the Company is or may become obligated
to issue, sell, purchase, return or redeem any Units, membership interests or any other securities or interests, and there are
no Equity Interests of the Company reserved for issuance for any purpose. The Company does not have any Contract to acquire any
capital stock of or other Equity Interest in any Person.


 


(b)          The
only Subsidiary of the Company is Talec Pharma, LLC. The Company is the sole record and beneficial owner and holder, free and
clear of all Encumbrances, of all of the Equity Interests of Talec Pharma, LLC. All of the Equity Interests of Talec Pharma, LLC
were issued in compliance with all applicable Legal Requirements. There are no outstanding warrants, options, agreements, convertible
or exchangeable securities or other agreements, arrangements or commitments of any character pursuant to which any Subsidiary
is or may become obligated to issue, sell, purchase, return or redeem any Equity Interests, membership interests or any other
securities or interests, and there are no Equity Interests of any Subsidiary reserved for issuance for any purpose. No Subsidiary
has any Contract to acquire any capital stock of or other Equity Interest in any Person.


 


2.4           Financial
Statements. Schedule 2.4


 


Contains the consolidated, unaudited balance
sheet of the Company Parties as of December 31, 2011 (the “Balance Sheet”, and such date the “Balance
Sheet Date”) and a consolidated, unaudited statement of income for the Company Parties for the year then ended (collectively,
the “Financial Statements”). The Financial Statements (i) fairly present in all material respects the results
of operations and financial position of the Company Parties for the periods and as of the dates referred to in the Financial Statements
and (ii) have been prepared in a manner consistent with the books and records of the Company Parties and in accordance with GAAP
throughout the periods covered thereby, subject to the absence of notes.


 




    	[Confidential Treatment Requested]

9



    	 



    

  


2.5           Absence
of Changes.


 


Since the Balance Sheet Date, except as set
forth on Schedule 2.5:


 


(a)          no
Company Party has declared, accrued, set aside or paid any dividend or made any other distribution in respect of any of its Equity
Interests, and has not repurchased, redeemed or otherwise reacquired any of its Equity Interests.


 


(b)          there
has been no amendment to the certificate of formation or other governing or organizational document of any Company Party, and
no Company Party has adopted, effected or been a party to any merger, recapitalization or reclassification of its Equity Interests;


 


(c)          no
Company Party has adopted any plan of consolidation, reorganization, liquidation or dissolution or filed a petition in bankruptcy
under any provisions of federal or state bankruptcy law or consented to the filing of any bankruptcy petition against it under
any similar law;


 


(d)          no
Company Party has formed any Subsidiary, made any capital investment in or acquired any equity interest in any other Entity;


 


(e)          the
Company Parties have not made any capital expenditures which exceed $75,000 in the aggregate;


 


(f)          no
Company Party has (i) entered into or permitted any of the assets owned or used by it to become bound by any Contract that contemplates
or involves (A) the payment or delivery of cash or other consideration in an amount or having a value in excess of $75,000 in
the aggregate, or (B) the lease, purchase or sale of any product, or performance of services by or to a Company Party having a
value in excess of $75,000 in the aggregate, or (ii) waived any right or remedy under any Contract other than in the Ordinary
Course of Business, or amended or prematurely terminated any Contract other than in the Ordinary Course of Business;


 


(g)          
no Company Party has (i) acquired, leased or licensed any right or other property or asset from any other Person, (ii) sold, transferred,
assigned or otherwise disposed of, or leased or licensed, any right, or other property or asset to any other Person, or (iii)
waived or relinquished any right, except, in each case, in the Ordinary Course of Business;


 


(h)          
no material damage, destruction or loss (whether or not covered by insurance) has occurred to any asset of any Company Party;


 


(i)          no
Company Party has made any pledge of any of its assets or otherwise permitted any of its assets to become subject to any material
Encumbrance other than Permitted Encumbrances, except for pledges of immaterial assets made in the Ordinary Course of Business;


 


(j)          no
Company Party has (i) lent money to any Person, (ii) incurred, assumed or guaranteed any indebtedness for borrowed money or (iii)
issued or sold any debt securities or options, warrants, calls or similar rights to acquire any debt securities of any Company
Party;


 


(k)          no
Company Party has changed any of its personnel policies or other business policies, or any of its methods of accounting or accounting
practices in any material respect;


 




    	[Confidential Treatment Requested]

10



    	 



    

 


(l)          no
Company Party has (i) granted any bonuses, whether monetary or otherwise, or increase in any wages, salary, severance, pension
or other compensation or benefits in respect of its employees, officers, directors, independent contractors or consultants, (ii)
changed the terms of employment for any employee or any termination of any employees for which the aggregate costs and expenses
exceed $10,000, or (iii) taken any action to accelerate the vesting or payment of any compensation or benefit for any employee,
officer, director, independent contractor or consultant;


 


(m)          no
Company Party has made any loan to (or forgiveness of any loan to) other than ordinary course expense advancements, or entered
into any other transaction with, any of its stockholders, directors, officers and employees;


 


(n)          no
Company Party has entered into a new line of business or abandoned or discontinued any existing line of business;


 


(o)          no
Company Party has (i) made any material Tax election, or adopted or changed any material accounting method in respect of Taxes,
(ii) entered into any closing agreement, settled or compromised any claim or assessment in respect of Taxes other than with respect
to a claim or assessment which existed on the date hereof and in an amount not greater than the liability or reserve that has
been recorded with respect thereto in the Balance Sheet, or (iii) consented to any extension or waiver of any limitation period
with respect to any claim or assessment for Taxes;


 


(p)          no
Company Party has threatened, commenced or settled any Legal Proceeding; and


 


(q)          no
Company Party has agreed to take, or committed to take, any of the actions referred to in clauses “(a)” through “(p)”
above.


 


2.6           Tax
Matters.


 


Except as set forth on Schedule 2.6, (a) the
Company Parties have prepared and timely filed (taking into account any extension of time within which to file) all Tax Returns
required to be filed by any of them prior to the Closing Date and all such filed Tax Returns are complete and accurate in all
material respects, (b) the Company Parties have paid all material Taxes that are required to be paid by any of them prior to the
Closing Date (whether or not shown on any Tax Return), (c) no claim has ever been made by a Tax Authority in a jurisdiction where
the Company Parties do not file Tax Returns claiming that any Company Party is or may be subject to taxation in that jurisdiction,
(d) the Company Parties have withheld and paid all material Taxes required to be withheld and paid in connection with amounts
paid or owing to any employee or member, (e) there are no Liens for Taxes (other than Taxes not yet due and payable) upon any
assets of any Company Party, (f) no deficiencies have been asserted in writing or assessed by any taxing authority against any
Company Party, (g) the Company Parties have not received written notice of any pending or threatened audits, examinations, investigations
or other proceedings in respect of any Taxes or Tax Returns of the Company Parties and there are no currently effective waivers
(or requests for waivers) of the time to assess any Taxes of the Company Parties, (h) no Company Party has participated in any
“reportable transaction” within the meaning of Treasury Regulation Section 1.6011-4(b)(2), (i) the Company is classified
as a corporation for U.S. federal income tax purposes, (j) no Company Party is a party to any Tax allocation or sharing agreement
or has been a member of an affiliated group filing a consolidated Tax Return or has any liability for the Taxes of any other person
under Treasury Reg. Section 1.1502-6 (or any similar provision) as a transferee or successor, by contract, or otherwise, (k) no
Company Party will be required to include any item of income in, or exclude any item of deduction from, taxable income for any
taxable period (or portion thereof) ending after the Closing Date as a result of (i) a change in method of accounting as described
in IRC Section 481, (ii) a “closing agreement” as described in IRC Section 7121 or (iii) an installment sale or open
sale transaction occurring before the Closing Date, (l) no Company Party is a party to any agreement, contract, arrangement or
plan that has resulted or could result, separately or in the aggregate, in the payment of any “excess parachute payment”
within the meaning of IRC Section 280G and (m) the Company Parties have made available to Buyer true, correct and complete copies
of all Tax Returns filed and Tax examination reports and Tax deficiencies received by the Company Parties.


 




    	[Confidential Treatment Requested]

11



    	 



    

 


2.7           Claims.


 


There are no claims or Legal Proceedings that
are currently pending against any Company Party, or to the Company’s Knowledge that are (a) threatened against any Company
Party or (b) that challenge, or reasonably could be expected to prevent or delay the transactions contemplated by this Agreement.


 


2.8           Compliance
with Laws.


 


(a)          Each
Company Party has complied and is now in compliance with all Legal Requirements applicable to it or its business, properties or
assets. No Company Party has received any written notice from any Governmental Body or any other Person regarding (i) any actual,
alleged or potential material violation of or material liability under any Legal Requirement, or (ii) any actual, alleged, or
potential material obligation of such Company Party to undertake or pay for any response action required by any Legal Requirement.


 


(b)          All
Governmental Authorizations required for each Company Party to conduct its business as currently conducted have been obtained
by it and are valid and in full force and effect. No Company Party holds any open Investigational New Drug (“IND”)
application or New Drug Application (“NDA”). All fees and charges with respect to such Governmental
Authorizations due and payable as of the date hereof have been paid in full, except for those fees and charges the failure of
which to pay in full would not, individually or in the aggregate, have an adverse effect on the material operations of the business,
or any fees payable to FDA. No event has occurred that, with or without notice or lapse of time or both, would reasonably be expected
to result in the revocation, suspension, lapse or limitation of any Governmental Authorizations of the Company Parties.


 


2.9           Employee
and Labor Matters; Benefit Plans.


 


(a)          The
Company has delivered to the Buyer a complete and accurate list of the name, job title, current annual compensation, accrued vacation
and severance pay of each officer, director and employee of the Company Parties. There is no Contract (i) for the employment of
any individual or (ii) relating to the payment of any severance or termination payment, bonus or employee benefit to any employee
or former employee.


 


(b)          The
Company is not a party to any collective bargaining agreement or other labor Contract. There is no pending or, to the Company’s
Knowledge, threatened (i) strike, slowdown or work stoppage, or (ii) application for certification of a collective bargaining
agent for any of the Company’s employees. There is no lockout of any employees of the Company, and no such action is contemplated
by the Company.


 




    	[Confidential Treatment Requested]

12



    	 



    

 


(c)          Schedule
2.9(c) lists any independent contractors who currently provide services to any Company Party.


 


(d)          No
Company Party has maintained, established, sponsored, participated in, or contributed to any: (i) employee benefit pension plan
(as defined in Section 3(2) of ERISA) (“Pension Plan”) subject to Title IV of ERISA; (ii) multiple employer
plan subject to Section 413 of the Code; (iii) multiemployer plan within the meaning of Section (3)(37) of ERISA; (iv) multiple
employer welfare arrangement subject to Section 3(40) of ERISA, or (v) a program or arrangement subject to Section 419, 419A or
501(c)(9) of the Code. No Company Party has maintained a Pension Plan or multiemployer plan, or the equivalent thereof, in a foreign
jurisdiction (a “Foreign Plan”).


 


(e)          No
Company Party (i) has been required to be treated as a single employer with any other Person under Section 4001(b)(1) of ERISA
or Section 414(b), (c), (m) or (o) of the Code, (ii) has been a member of an “affiliated service group” within the
meaning of Section 414(m) of the Code, or (iii) has made a complete or partial withdrawal from a multiemployer plan, as such term
is defined in Section 3(37) of ERISA, resulting in “withdrawal liability,” as such term is defined in Section 4201
of ERISA (without regard to subsequent reduction or waiver of such liability under either Section 4207 or 4208 of ERISA).


 


2.10         Insurance.


 


The Company Parties maintain the insurance
coverage set forth on Schedule 2.10. No Company Party has received any written notice or other communication regarding any actual
or possible (a) cancellation or invalidation of any insurance policy, (b) refusal of any coverage or rejection of any claim under
any insurance policy, or (c) material adjustment in the amount of the premiums payable with respect to any insurance policy.


 


2.11         Real
Property. Schedule 2.11


 


identifies all real property leased by any
Company Party and the lease agreement related thereto, copies of which have been made available to the Buyer (the “Leased
Real Property”). No Company Party owns any real property.


 


2.12         Bank
Accounts. Schedule 2.12


 


lists each bank account maintained by the Company
Parties at any bank or other financial institution, including the name of the bank or financial institution, the account number
and the names of all individuals authorized to draw on or make withdrawals from such accounts.


 


2.13         Regulatory
Compliance.


 


(a)          No
Company Party has received any notices or correspondence from the FDA or any Governmental Body exercising comparable authority
requiring the recall, termination or suspension of sale of the Product or otherwise alleging that any Company Party is not in
compliance in all material respects with all applicable Legal Requirements.


 




    	[Confidential Treatment Requested]

13



    	 



    

 


(b)          Neither
the Company nor any of its officers and employees, nor, to the Company’s Knowledge, any of its agents and contractors is
the subject of any pending or threatened investigation by FDA pursuant to its “Fraud, Untrue Statements of Material Facts,
Bribery, and Illegal Gratuities” Final Policy set forth in 56 Fed. Reg. 46191 (September 10, 1991) and any amendments thereto,
or by any other comparable Governmental Body to invoke any similar policy. Neither the Company nor any of its officers and employees,
nor, to the Company’s Knowledge, any of its agents and contractors has (A) made any untrue statement of material fact or
fraudulent statement to FDA, DEA, or any other Governmental Body; (B) failed to disclose a material fact required to be disclosed
to FDA, DEA, or any other Governmental Body, or (C) committed an act, made a statement, or failed to make a statement that would
reasonably be expected to provide the basis for the FDA or any other Governmental Body to invoke FDA’s “Fraud, Untrue
Statements of Material Facts, Bribery, and Illegal Gratuities” Final Policy.


 


(c)          Neither
the Company, nor its officers or employees have been debarred or have been convicted of any crime or engaged in any conduct that
did or could result in debarment under 21 U.S.C. § 335a, exclusion from federal healthcare programs under 42 U.S.C. §
1320a7, disqualification as a clinical investigator under 21 C.F.R. § 312.70 or any similar Legal Requirements, and neither
the Company nor any of its officers or employees, has engaged in any conduct that would reasonably be expected to result in debarment,
exclusion, or disqualification from U.S. federal health care programs.


 


(d)          Neither
the Company nor any of its officers has received any written notice or communication from the FDA, DEA, or other Governmental
Body requiring termination or suspension of sale of the Product or alleging noncompliance with any applicable FDA Law, DEA Law,
or other applicable Legal Requirements with regard to the Product or any Launch Product. Neither the Company nor any of its officers
has been or is subject to any enforcement proceedings by the FDA, DEA, or other Governmental Body and, to the Company’s
Knowledge, no such proceedings have been threatened.


 


2.14         Accounts
Receivable.


 


All accounts receivable of the Company Parties
represent valid, undisputed and bona fide claims of the Company not subject to claims of set-off or other defenses or counterclaims
other than normal cash discounts accrued in the Ordinary Course of Business.


 


2.15         Proprietary
Rights.


 


(a)          Schedule
2.15(a) lists each registered Proprietary Right that the Company Parties use in their business. The Company Parties own or
have the right to use all of the Proprietary Rights that the Company Parties use in their business. Except as disclosed in Schedule
2.15(a), the Company Parties have no obligation to pay any royalty to any Person relating to any Proprietary Right used by
the Company.


 


(b)          To
the Company’s Knowledge, (i) no Company Party is infringing upon any Proprietary Right of any other Person and (ii) no Person
is infringing upon any Proprietary Right of any Company Party. No claims are pending against any Company Party by any Person:
(A) that such Person has any right, title or interest in or to any of the Company Parties’ Proprietary Rights; (B) that
such Person has the right to use any of the Company Parties’ Proprietary Rights; or (C) to the effect that any action by
any Company Party infringes any Proprietary Right of such Person.




    	[Confidential Treatment Requested]

14



    	 



    

 


2.16         Supply
Arrangement. Schedule 2.17


 


sets forth a list of all supply agreements
for goods or services related to the Product and Launch Products (“Product Suppliers”). No Company Party has
received any written notice that any of its Product Suppliers has ceased, or intends to cease, to supply goods or services or
to otherwise terminate or materially reduce its relationship with such Company Party.


 


2.17         Contracts.


 


(a)          Schedule
2.17(a) sets forth a complete and accurate list of each Contract of any Company Party that falls into one or more of the following
categories:


 


(i)          is
a Contract that is or relates to the performance of services or delivery of goods or materials of an amount or value in excess
of $50,000 per year and is not cancelable without penalty on 120 days’ notice or less;


(ii)         
is a Contract that is or relates to the grant or receipt by a Company Party of any license or royalty fees or other similar payment
obligations to or from any Person in excess of $50,000 per year;


 


(iii)        is
a Contract that is a lease agreement with respect to real property;


 


(iv)        is
a Contract of any Company Party with any other Company Party, the Seller or any affiliate of the Seller;


 


(v)         is
a Contract with investment bankers, financial advisors, attorneys, accountants or other advisors retained by any Company Party
involving payments by any Company Party of more than $50,000 on an annual basis;


 


(vi)        is
a Contract that provides for the indemnification by any Company Party of any person except for any such Contract that was entered
into in the Ordinary Course of Business;


 


(vii)       is
a Contract pursuant to which any indebtedness of the Company Parties is outstanding or may be incurred and all guarantees of or
by the Company Parties of any indebtedness of any other person (excluding trade payables in the Ordinary Course of Business);


 


(viii)      is
a partnership, joint venture agreement or other similar agreement involving co-investment with a third party to which any Company
Party is a party;


 


(ix)         is
a Contract with a Governmental Body which imposes any material obligation or restriction on any Company Party; or


 


(x)          is
a Contract that contains non-competition, exclusivity, or other covenants limiting or restricting the ability of a Company Party
to engage directly or indirectly in any business.


 


The contracts or instruments required to be set forth in Schedule
2.17(a) are referred to herein as the “Material Contracts.”


 


(b)          The
Company has heretofore delivered to the Buyer true and complete copies of all the Material Contracts.


 




    	[Confidential Treatment Requested]

15



    	 



    

 


(c)          Each
of the Material Contracts is in full force and effect, constitutes a valid and binding obligation of a Company Party and, to the
Company’s Knowledge, the other parties thereto, is legally enforceable against such Company Party and, to the Company’s
Knowledge, the other parties thereto, in accordance with its terms, except as enforcement may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium, fraudulent transfer or other laws relating to or limiting creditor’s rights generally
or by general principles of equity.


 


(d)          No
Company Party is in breach or default in any material respect under any Material Contract and, to the Company’s Knowledge,
no other party to any of the Material Contracts is in breach or default in any material respect thereunder.


 


2.18         Title
to Assets.


 


The Company has good and valid title to, or
a valid leasehold interest in, all real property and personal property and other assets reflected in the Financial Statements
or acquired after the Balance Sheet Date, other than properties and assets sold or otherwise disposed of in the Ordinary Course
of Business since the Balance Sheet Date.


 


2.19         Necessary
Assets.


 


The Leased Real Property, the Proprietary Rights,
the tangible personal property owned by the Company Parties and all other assets owned, licensed or leased by the Company Parties
constitute all of the assets that are necessary to permit the Buyer to operate the Company Parties’ business immediately
after the Closing Date in substantially the same manner as it is operated immediately prior to the Closing Date.


 


2.20         No
State Antitakeover Statute.


 


There is no state business combination, control
share or other antitakeover statute or similar statute or regulation that is or becomes operative with respect to this Agreement
or any of the transactions contemplated by this Agreement. If any such state business combination, control share or other antitakeover
statute or similar statute or regulation is or becomes operative with respect to this Agreement or any of the transactions contemplated
by this Agreement, the Company has taken all actions necessary to ensure that this Agreement and any of the transactions contemplated
by this Agreement may be consummated as promptly as practicable on the terms contemplated by this Agreement and otherwise to minimize
the effect of such statute or regulation.


 


2.21         Brokers.


 


No broker, finder or other Person is or will
be entitled to any brokerage fees, commissions or finder’s fees from the Seller or any Company Party or by reason of any
action taken by the Seller or any Company Party.


 




    	[Confidential Treatment Requested]

16



    	 



    

 


2.22         Transaction
Payments.


 


There are no payments payable by the Company
to any director, officer, employee or former director, officer or employee of the Company arising at or prior to the Closing from
or as a result of the consummation of the transactions contemplated by this Agreement, including any payments for stock appreciation
or similar rights, any severance or bonus plan payment, any payment of deferred compensation, any transaction bonus or change
in control payment, or any similar payment (“Company Transaction Payments”). As of the Closing, there are no
outstanding or unsatisfied Company Transaction Payments.


 


2.23         No
Other Representations or Warranties.


 


EXCEPT AS EXPRESSLY SET FORTH IN THIS SECTION
2 AND SECTION 3, NEITHER THE SELLER NOR THE COMPANY MAKES, AND NO PARTY SHALL BE ENTITLED TO RELY UPON, ANY REPRESENTATION OR
WARRANTY AS TO ANY FACT OR MATTER ABOUT THE COMPANY PARTIES OR THE SELLER.


 


3.          REPRESENTATIONS
AND WARRANTIES OF THE SELLER


 


The Seller represents
and warrants to the Buyer as follows.


 


3.1           Organization;
Good Standing.


 


The Seller is duly organized, validly existing
and in good standing under the laws of the state of its formation.


 


3.2           Authority;
Enforceability. 


 


The Seller has the absolute and unrestricted
right, authority, power and capacity to (i) execute and deliver each certificate, document and agreement to be executed by the
Seller in connection herewith (collectively, the “Seller Documents”) and (ii) perform its obligations thereunder.
The execution and delivery of the Seller Documents and the consummation of the transactions contemplated thereby have been duly
and validly authorized by the Seller. Each Seller Document has been duly and validly executed and delivered by the Seller and
constitutes the legal, valid and binding obligation of the Seller, enforceable against it in accordance with its terms except
(x) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and other similar Legal
Requirements of general application affecting enforcement of creditors’ rights generally and (y) the availability of the
remedy of specific performance or injunctive or other forms of equitable relief may be subject to equitable defenses and would
be subject to the discretion of the court before which any such proceeding may be brought.


 




    	[Confidential Treatment Requested]

17



    	 



    

 


3.3           Consents
and Approvals; No Violation. 


 


Neither the execution and delivery of the Seller
Documents by the Seller nor the performance of its obligations thereunder nor the consummation by the Seller of the transactions
contemplated thereby will: (i) conflict with or result in a breach, violation, or default of or under, (ii) give any third party
the right to modify, terminate or accelerate any liability or obligations of, (iii) result in the creation of any Encumbrance
(other than Permitted Encumbrances) on the Units, or (iv) require any Consent by or declaration or notice to any third party or
Governmental Body pursuant to (A) the certificate of formation or other governing documents of the Seller or (B) any Legal Requirement.


 


3.4           No
Other Representations or Warranties.


 


EXCEPT AS EXPRESSLY SET FORTH IN THIS SECTION
3 AND SECTION 2, NEITHER THE SELLER NOR THE COMPANY MAKES, AND NO PARTY SHALL BE ENTITLED TO RELY UPON, ANY REPRESENTATION OR
WARRANTY AS TO ANY FACT OR MATTER ABOUT THE COMPANY PARTIES OR THE SELLERS.


 


4.          REPRESENTATIONS
AND WARRANTIES OF THE BUYER


 


The Buyer represents and
warrants to the Seller as follows.


 


4.1           Organization;
Good Standing.


 


The Buyer is duly organized, validly existing
and in good standing under the laws of Delaware. The Buyer has the requisite power and authority to own, lease or use its properties
and assets and to conduct its business as presently conducted.


 


4.2           Authority;
Enforceability.


 


The Buyer has the absolute and unrestricted
right, authority, power and capacity to (i) execute and deliver each certificate, document and agreement to be executed by the
Buyer in connection herewith (collectively, the “Buyer Documents”) and (ii) perform its obligations thereunder.
The execution and delivery of the Buyer Documents and the consummation of the transactions contemplated thereby have been duly
and validly authorized by the Buyer. Each Buyer Document has been duly and validly executed and delivered by the Buyer and constitutes
the legal, valid and binding obligation of the Buyer, enforceable against it in accordance with its terms except (x) as limited
by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and other similar Legal Requirements of
general application affecting enforcement of creditors’ rights generally and (y) the availability of the remedy of specific
performance or injunctive or other forms of equitable relief may be subject to equitable defenses and would be subject to the
discretion of the court before which any such proceeding may be brought.


 




    	[Confidential Treatment Requested]

18



    	 



    

  


4.3           Consents
and Approvals; No Violation.


 


Neither the execution and delivery of the Buyer
Documents by the Buyer nor the performance of its obligations thereunder nor the consummation by the Buyer of the transactions
contemplated thereby will: (i) conflict with or result in a breach, violation, or default of or under, (ii) give any third party
the right to modify, terminate or accelerate any liability or obligations of, (iii) result in the creation of any Encumbrance
(other than Permitted Encumbrances) on the assets of the Buyer under or pursuant to, or (iv) require any Consent by or declaration
or notice to any third party or Governmental Body pursuant to (A) the governing documents of the Buyer, (B) any Buyer Contracts,
or (C) any Legal Requirement.


 


4.4           No
Restrictions.


 


There are no restrictions on, or conditions
to, the Buyer’s ability to make all of the payments contemplated in this Agreement in any Contract of the Buyer (including
any loan agreement, note, indenture or similar financing document).


 


4.5           No
Other Representations or Warranties.


 


EXCEPT AS EXPRESSLY SET
FORTH IN THIS SECTION 4, THE BUYER DOES NOT MAKE, AND NO PARTY SHALL BE ENTITLED TO RELY UPON, ANY REPRESENTATION OR WARRANTY
AS TO ANY FACT OR MATTER ABOUT THE BUYER.


 


5. ADDITIONAL AGREEMENTS OF THE PARTIES


 


5.1 Indemnification of Officers and Directors.


 


(a) The Company shall
purchase, at its sole cost and expense, and pay all premiums under, a six-year tail insurance policy, with an effective date as
of the Closing Date, which maintains in effect for six years from the Closing Date the current directors’ and officers’
liability insurance policies maintained by the Company Parties on terms and conditions that are not materially less favorable
than those of such policy in effect as of the date hereof.


 


(b) Subject to the Buyer’s
rights to indemnification as provided in Section 6.2, from and after the Closing Date for a period of six years, the Company
shall fulfill and honor in all respects the obligations of the Company pursuant to any required indemnification provisions of
the Company under its certificate of formation and Operating Agreement as are in effect on the date of this Agreement; provided
that such indemnification shall be subject to any limitation imposed from time to time under any Legal Requirements, including
the DGCL.


 




    	[Confidential Treatment Requested]

19



    	 



    

  


5.2 Disclosure.


 


Without limiting any Party’s
obligations under existing confidentiality agreements, each Party shall not, and shall not permit any of its Subsidiaries or any
Representative of such Party to, issue any press release or make any disclosure regarding the transactions contemplated hereunder
unless: (a) the other Parties shall have approved such press release or disclosure in writing; or (b) such Party shall have determined
in good faith, upon the advice of outside legal counsel, that such disclosure is required by applicable Legal Requirements or
stock exchange rule or regulation and, to the extent practicable, before such press release or disclosure is issued or made, such
Party advises the other Parties of, and consults with the other Parties regarding, the text of such press release or disclosure.
Notwithstanding the foregoing, nothing in this Section 5.2 shall prevent a Party from making disclosures: (a) to Persons
employed or engaged by such Party in evaluating, approving, structuring or administering this Agreement, so long as such Persons
are notified of, and agree to maintain, the confidential nature of such information; (b) to such Party’s legal counsel or
accountants, partners or investors (including outside auditors and legal counsel of such Party’s accountants, partners or
investors) or to such Party’s employees, officers, directors or affiliates, so long as such Persons are notified of, and
agree to maintain, the confidential nature of such information; (c) to any investor or potential investor of such Party, in connection
with investment decisions with respect to such Party or otherwise in connection with customary reports to such investors or potential
investors regarding such Party’s portfolio and performance, so long as such Persons are notified of, and agree to maintain,
the confidential nature of such information; or (d) to any assignee or potential assignee that has agreed to comply with the covenant
contained in this Section 5.2 (and any such assignee or potential assignee may disclose such information to Persons employed
or engaged by it as described in clauses (a) - (c) above).


 


5.3 Maintenance of Books and Records.


 


Each of the Buyer, Seller
and the Company Parties shall preserve all pre-Closing Date records possessed by or under the control of such party relating to
the Company Parties in accordance with the Company’s existing document retention policies and procedures. During the five
year period following the Closing Date, upon any reasonable request from the Buyer or the Seller or any of their respective Representatives,
the party holding such records shall provide to the requesting party or its Representatives reasonable access to such records
during normal business hours at the cost of the requesting party or its Representatives. Records may be sought under this Section
5.3 for any reasonable purpose, including to the extent reasonably required in connection with the audit, accounting, Tax,
litigation, federal securities disclosure or other similar proper business purpose of the party seeking such records. Neither
Buyer nor Seller shall be obligated to provide the other party with access to any books and records pursuant to this Section
5.3 where such access would violate any Legal Requirement.


 


5.4 Taxes.


 


(a) The Company shall
(and the Buyer shall cause the Company to), at the Company’s expense, engage and direct the Company’s existing accounting
firm, Swink, Fiehler & Co., P.C., to prepare any and all Tax Returns for all Tax periods that end on or before the Closing
Date; provided, that such Tax Returns shall be prepared in a manner consistent with past practices for Tax Returns (unless
otherwise required by applicable Legal Requirements) from periods prior to the Closing. At least 20 days prior to the due date
for filing any such Tax Return, the Company shall deliver, or caused to be delivered, to the Seller such Tax Return for its review
and approval. Unless the Seller gives written notice to the Company at least 5 days prior to the due date for filing any such
Tax Return specifying in reasonable detail all disputed items and the basis therefor, the Seller shall be deemed to have accepted
and agreed to such Tax Return. The Seller shall pay to the applicable Tax authority any Taxes due on such Tax Returns to the extent
not taken into account in determining the Adjusted Working Capital.


 




    	[Confidential Treatment Requested]

20



    	 



    

 


(b) If the Seller timely
notifies the Company of its objection to any Tax Return prepared hereunder, the Buyer, the Company and the Seller shall, within
the next 5 days (the “Tax Resolution Period”), attempt to resolve their differences and any resolution
by them as to any disputed amounts shall be final, binding and conclusive. If at the conclusion of the Tax Resolution Period amounts
remain in dispute, then all amounts remaining in dispute shall then be submitted, as soon as practicable, to the Reviewing Accountant.
The parties agree to execute a reasonable engagement letter if requested by the Reviewing Accountant. The Reviewing Accountant
shall act as an arbitrator to determine only those issues still in dispute.


The Reviewing Accountant’s determination
shall be made within 30 days after their selection, shall be set forth in a written statement delivered to the Buyer, the Company
and the Sellers and shall be final, binding and conclusive. If a draft Tax Return is subject to an ongoing dispute under this
Section 5.4(b) at the time that it is required to be filed, then such Tax Return shall be filed as initially prepared by
the filing party, with an amended Tax Return reflecting the resolution by the Reviewing Accountant to be filed following the Reviewing
Accountant’s resolution of the dispute. All fees and expenses of the Reviewing Accountant in connection with any dispute
submitted to the Reviewing Accountant shall be allocated between the Buyer and the Seller in the same proportion that such party’s
aggregate dollar amount of unsuccessfully disputed items submitted to the Reviewing Accountant bears to the total dollar amount
of disputed items so submitted.


(c) After the Closing,
upon reasonable written notice, the Buyer (or the Company Parties) and the Seller shall furnish or cause to be furnished to each
other, as promptly as practicable, such information and assistance (to the extent within the control of such party) relating to
the Company Parties (including access to books, records and personnel) as is reasonably requested for the filing of all Tax Returns
(including any extensions thereof), the making of any election related to Taxes, the preparation for any audit, and the prosecution
or defense of any action related to any Tax Return. The Buyer and the Company Parties agree to retain all books and records with
respect to Tax matters and pertinent to the Company Parties relating to any taxable period beginning before the Closing Date until
the expiration of the statute of limitations.


 


(d) Neither the Buyer
nor any Company Party may amend a Tax Return of any of the Company Parties with respect to a taxable period beginning before the
Closing Date, or file or amend any tax election with respect to any of the Company Parties with respect to a taxable period beginning
before the Closing Date, in each case, without the prior written consent of the Seller (which consent may not be unreasonably
withheld or delayed).


 


(e) Except as otherwise
provided in this Section 5.4, to the extent any determination of the Taxes of any of the Company Parties, whether as a
result of an audit, a claim for refund, the filing of an amended Tax Return, or otherwise, results in any refund or credit of
Taxes paid by the Company Parties for any period prior to the Closing Date, the Buyer shall cause the applicable Company Parties
to promptly pay any such refund or credit, and any interest received thereon, to the Seller upon receipt or realization thereof;
provided, that, no such refund shall be payable with respect to the carryback of net operating losses, credits or
other tax attributes generated in Tax periods or any portion thereof beginning after the Closing Date, or with respect to any
amounts taken into account in determining the Adjusted Working Capital.


 


(f) The Buyer shall file
a consolidated (or combined, as applicable) federal and state tax return that includes the Company Parties for the Buyer's taxable
year ending after the Closing Date.


 




    	[Confidential Treatment Requested]

21



    	 



    

  


5.5 Eclat Name.


 


Seller acknowledges and
agrees that as of the Effective Time, the“Éclat” name and any associated trademarks, service marks, trade names,
brand names, logos, trade dress and other proprietary indicia of goods and services, whether registered or unregistered, shall
be part of the Intellectual Property transferred to Buyer. Seller further acknowledges and agrees, effective as of the Effective
Time, to change the name of the Seller to delete any reference to the name “Éclat” and to take such actions
and make such filings with the Secretary of State of the State of Delaware to effect such name change, and to transfer to the
Buyer or abandon (as directed by the Buyer) any domain name that includes or is confusingly similar to any name, logo, or domain
name that was included in the Company Intellectual Property or Licensed Intellectual Property. After the Closing Date, Seller
further acknowledges and agrees not to use the name “Éclat”, “Hycet”, or any confusingly similar
name or mark as or in a company or subsidiary name or in connection with any of Seller’s or its affiliates’ future
products or services, and further agrees to register or use any name, logo, or domain name that includes or is confusingly similar
to any name, logo, or domain name that was included in the Company Intellectual Property or Licensed Intellectual Property.


5.6 Further Assurances. Following the Closing, each of the
Parties hereto shall, and shall cause their respective affiliates to, execute and deliver such additional documents, instruments,
conveyances and assurances and take such further actions as may be reasonably required to carry out the provisions hereof and
give effect to the transactions contemplated by


 


6.          INDEMNIFICATION


 


6.1           Survival.


 


Subject to the limitations
and other provisions of this Agreement, the representations and warranties contained herein shall survive the Closing and shall
remain in full force and effect until the date that is three (3) years from the Closing Date; provided, that the Fundamental Representations
and the representations and warranties in Article 4 shall survive indefinitely and the representations and warranties in
Section 2.6 (Tax Matters), Section 2.8 (Compliance With Laws), Section 2.9 (Employee and Labor Matters;
Benefit Plans), Section 2.13 (Regulatory Compliance) and Section 2.15 (Proprietary Rights) shall survive for the
full period of all applicable statutes of limitations (giving effect to any waiver, mitigation or extension thereof) plus 60 days.
All covenants and agreements of the parties contained herein shall survive the Closing indefinitely or for the period explicitly
specified therein.


Notwithstanding the foregoing, any claims
asserted in good faith with reasonable specificity (to the extent known at such time) and in writing by notice from the non-breaching
party to the breaching party prior to the expiration date of the applicable survival period shall not thereafter be barred by
the expiration of the relevant representation or warranty, and such claims shall survive until finally resolved.


 


6.2           Seller
Indemnification.


 


Subject to the limitations
set forth in this Section 6, the Buyer shall be entitled to be indemnified and held harmless solely out of a right of set-off
against amounts due under the Note, any Launch Products Deferred Payment or any Hycet Deferred Payment, as applicable in accordance
with Section 6.6, for any and all losses, damages, liabilities, deficiencies, judgments, interest, penalties, fines and
costs or expenses of whatever kind, including reasonable attorneys' fees, resulting from:


 


(a)          any
inaccuracy in or breach of any representation or warranty contained in Section 2 or Section 3 of this Agreement;
and


 


(b)          any
breach or non-fulfillment of any covenant, agreement or obligation to be performed by Seller pursuant to this Agreement.


 




    	[Confidential Treatment Requested]

22



    	 



    

 


6.3           Buyer
Indemnification.


 


The Buyer shall indemnify
and hold harmless the Seller for, and shall pay to the Seller, any and all losses, damages, liabilities, deficiencies, judgments,
interest, penalties, fines and costs or expenses of whatever kind, including reasonable attorneys' fees, resulting from:


 


(a)          any
inaccuracy in or breach of any representation or warranty contained in Section 4 of this Agreement; and


 


(b)          any
breach or non-fulfillment of any covenant, agreement or obligation to be performed by Buyer pursuant to this Agreement.


 


6.4           Limitations.


 


Notwithstanding anything
set forth in this Agreement to the contrary:


 


(a)          The
Seller shall not have any liability under this Agreement other than a right of the Buyer to set-off against amounts due under
the Note in accordance with Section 6.6 and shall not have any liability in the aggregate at any time in excess of an amount
equal to the amounts due under the Note; provided, however, that the foregoing limitation shall not apply to recovery under Section
6.2(a) for any inaccuracy in or breach of any Fundamental Representations or the representations and warranties in Section
2.8 (Compliance With Laws), for which the Buyer shall also be entitled to set-off against the Launch Products Deferred Payments
and the Hycet Deferred Payments in accordance with Section 6.6.


 


(b)          The
Buyer shall not be entitled to recovery under Section 6.2(a) unless the amount of damages resulting from an individual
breach of the representations and warranties (or series of related breaches) exceeds $5,000.


 


(c)          Except
for breaches of any Fundamental Representations, the Buyer shall not be entitled to recovery under Section 6.2(a) unless
and until the aggregate amount of the damages due to the Buyer exceeds $90,000, in which event the Buyer shall be entitled to
recovery for the full amount of damages from the first dollar.


 


(d)          For
purposes of this Section 6, any inaccuracy in or breach of any representation or warranty shall be determined without regard
to any materiality or other similar qualification contained in or otherwise applicable to such representation or warranty.


 


(e)          The
Buyer shall not be entitled to recovery for any damages to the extent such damages are reserved for as a liability or contra-asset
in the Closing Balance Sheet as finally determined in accordance with this Agreement and are taken into account in the determination
of the Adjusted Working Capital.


 


(f)          All
damages recoverable by the Buyer as a right of the Buyer to set-off against amounts due under the Note, the Launch Products Deferred
Payments and/or the Hycet Deferred Payments, as applicable, in accordance with Section 6.6 shall be net of any proceeds the Buyer
actually recovers under any available insurance less any related costs and expenses, including the aggregate cost of pursuing
any related insurance claims and any related increases in insurance premiums. Following the Closing, the Buyer and the Company
Parties shall use commercially reasonable efforts to claim and recover in full any damages or losses under any insurance policies
maintained by or for the benefit of the Buyer or the Company Parties or otherwise covering the business of the Company Parties
if and to the extent they are seeking indemnification for such damages or losses hereunder.


 




    	[Confidential Treatment Requested]

23



    	 



    

 


(g)          Notwithstanding
any other provision in this Agreement to the contrary, the Buyer shall not be entitled to a right of set-off against amounts due
under the Note, the Launch Products Deferred Payments and/or the Hycet Deferred Payments, as applicable, in accordance with Section
6.6 for any for damage to reputation, lost business opportunities, lost profits, mental or emotional distress, incidental,
special, consequential, exemplary, punitive, or indirect damages, interference with business operations or diminution in value.


 


(h)          All
amounts recovered by the Buyer as a right of set-off against amounts due under the Note, the Launch Products Deferred Payments
and/or the Hycet Deferred Payments, as applicable, in accordance with Section 6.6 shall be treated by the Parties as an
adjustment to the consideration for the Units.


 


6.5           Procedure
for Indemnification – Third-Party Claims.


 


(a)          If
the Buyer shall claim a right of set-off against amounts due under the Note, the Launch Products Deferred Payments and/or the
Hycet Deferred Payments, as applicable, in accordance with Section 6.6 hereunder arising from any claim or demand of a
third party, the Buyer shall notify the Seller in writing of the basis for such claim or demand and such notice shall set forth
the nature of the claim or demand in reasonable detail.


 


(b)          If
any Legal Proceeding is brought by a third party against the Buyer and the Buyer gives notice to the Seller pursuant to Section
6.5(a), the Seller shall be entitled to participate in such Legal Proceeding and, to the extent that it wishes, to assume
the defense of such Legal Proceeding if (i) the Seller provides written notice to the Buyer that the Seller intends to undertake
such defense and (ii) the Seller conducts the defense of the third-party claim diligently. The Buyer shall, in its sole discretion,
have the right to employ separate counsel (who may be selected by the Buyer in its sole discretion) in any such action and to
participate in the defense thereof, and the fees and expenses of such counsel shall be paid by the Buyer. The Buyer shall cooperate
in all reasonable respects with the Seller and its counsel in the defense or compromise of such claim or demand. If the Seller
assumes the defense of a Legal Proceeding, no compromise or settlement of such claims may be effected by the Seller without the
Buyer’s consent unless (A) there is no finding or admission of any violation of law or any violation of the rights of any
Person and no material adverse effect on the Buyer with respect to any other claims that may be made against it or (B) the sole
relief provided is monetary damages that are paid in full as a right of set-off against amounts due under the Note, the Launch
Products Deferred Payments and/or the Hycet Deferred Payments, as applicable, in accordance with Section 6.6.


 


(c)          If
(i) notice is given to the Seller of the commencement of any third-party Legal Proceeding and the Seller does not, within thirty
days after the Buyer’s notice is given, give notice to the Buyer of its election to assume the defense of such Legal Proceeding
or (ii) any of the conditions set forth in clauses (i) - (ii) of Section 6.5(b) above become unsatisfied, the Buyer shall
(upon notice to the Seller) have the right to undertake the defense, compromise or settlement of such claim; provided that
no compromise or settlement of such claim may be affected by the Buyer without the Seller’s consent, which shall not be
unreasonably withheld or delayed, if (A) the Buyer will receive as a right of set-off against amounts due under the Note and/or
the Launch Products Deferred Payments, as applicable, in accordance with Section 6.6 any amounts to be paid to compromise
or settle the claim, (B) there is a finding or admission of any violation by the Seller of any Legal Requirement or the rights
of any Person, or (C) the compromise or settlement would have a material adverse effect on the Seller with respect to any other
claims that may be made against it.


 




    	[Confidential Treatment Requested]

24



    	 



    

 


6.6           Right
of Set-Off.


 


The Buyer shall be entitled
to set off and reduce the amounts due under the Note by any amount it is entitled to recover under Section 6.2 (subject
to the limitations set forth in this Section 6), but only if such amount (i) has been mutually agreed in writing by the
Seller and the Buyer to be indemnifiable under Section 6.2 or (ii) has been determined by a final, nonappealable judgment
of a court of competent jurisdiction to be indemnifiable under Section 6.2. The Buyer shall be entitled to set off and
reduce the amounts due under the Note, the Launch Products Deferred Payments and/or the Hycet Deferred Payments by any amount
it is entitled to recover under Section 6.2(a) for any inaccuracy in or breach of any Fundamental Representations or the
representations and warranties in Section 2.8 (Compliance With Laws), subject to the limitations set forth in this Section
6, but only if such amount (i) has been mutually agreed in writing by the Seller and the Buyer to be indemnifiable under Section
6.2 or (ii) has been determined by a final, nonappealable judgment of a court of competent jurisdiction to be indemnifiable
under Section 6.2.


 


6.7           Exclusive
Remedy.


 


Except for claims of fraud,
criminal activity or willful misconduct, the right of the Buyer to set-off against amounts due under the Note, the Launch Products
Deferred Payments and/or the Hycet Deferred Payments, as applicable, in accordance with Section 6.6 for damages under Section
6.2 shall constitute the Buyer’s sole and exclusive remedy with respect to any and all claims arising under or relating
to this Agreement whether for breach of contract, in tort or otherwise (including for breach of any representation, warranty,
covenant or agreement), any agreement or document executed and delivered pursuant to this Agreement and the transactions contemplated
by this Agreement. Without limiting the generality of the foregoing, the Parties shall have no right of rescission following the
Closing with respect to the transactions contemplated by this Agreement.


 


7.          MISCELLANEOUS
PROVISIONS


 


7.1           Amendment.


 


This Agreement may not
be amended except by an instrument in writing signed on behalf of each of Party.


 


7.2           Waiver.


 


(a)          No
failure on the part of any Party to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part
of any Party in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power,
right, privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any
other or further exercise thereof or of any other power, right, privilege or remedy.


 




    	[Confidential Treatment Requested]

25



    	 



    

 


(b)          No
Party shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or remedy under this
Agreement, unless the waiver of such claim, power, right, privilege or remedy is expressly set forth in a written instrument duly
executed and delivered on behalf of such Party; and any such waiver shall not be applicable or have any effect except in the specific
instance in which it is given.


 


7.3 Entire Agreement; Counterparts; Exchanges
by Facsimile.


 


This Agreement, and the
other agreements referred to in this Agreement constitute the entire agreement and supersede all prior agreements and understandings,
both written and oral, among or between any of the Parties with respect to the subject matter hereof and thereof; provided,
however, that any existing confidentiality agreements shall not be superseded and shall remain in full force and effect
in accordance with its terms. This Agreement may be executed in several counterparts, each of which shall be deemed an original
and all of which shall constitute one and the same instrument. The exchange of a fully executed Agreement (in counterparts or
otherwise) by all Parties by facsimile or portable document format (PDF) shall be sufficient to bind the Parties to the terms
and conditions of this Agreement.


 


7.4 Applicable Law; Jurisdiction.


 


THIS AGREEMENT SHALL BE
GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF DELAWARE, REGARDLESS OF THE LAWS THAT MIGHT OTHERWISE
GOVERN UNDER APPLICABLE PRINCIPLES OF CONFLICTS OF LAWS. FLAMEL HEREBY IRREVOCABLY WAIVES ITS RIGHTS UNDER ARTICLE 14 AND ARTICLE
15 OF THE FRENCH CIVIL CODE. EACH OF THE PARTIES TO THIS AGREEMENT (A) CONSENTS TO SUBMIT ITSELF TO THE PERSONAL JURISDICTION
OF THE COURT OF CHANCERY OF THE STATE OF DELAWARE IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR
ANY OF THE TRANSACTIONS CONTEMPLATED HEREUNDER, (B) AGREES THAT ALL CLAIMS IN RESPECT OF SUCH ACTION OR PROCEEDING MAY BE HEARD
AND DETERMINED IN SUCH COURT, (C) AGREES THAT IT SHALL NOT ATTEMPT TO DENY OR DEFEAT SUCH PERSONAL JURISDICTION BY MOTION OR OTHER
REQUEST FOR LEAVE FROM ANY SUCH COURT, AND (D) AGREES NOT TO BRING ANY ACTION OR PROCEEDING (INCLUDING COUNTER-CLAIMS) ARISING
OUT OF OR RELATING TO THIS AGREEMENT OR ANY OF THE TRANSACTIONS CONTEMPLATED HEREUNDER IN ANY OTHER COURT. EACH OF THE PARTIES
WAIVES ANY DEFENSE OF INCONVENIENT FORUM TO THE MAINTENANCE OF ANY ACTION OR PROCEEDING SO BROUGHT AND WAIVES ANY BOND, SURETY
OR OTHER SECURITY THAT MIGHT BE REQUIRED OF ANY OTHER PARTY WITH RESPECT THERETO. ANY PARTY MAY MAKE SERVICE ON ANOTHER PARTY
BY SENDING OR DELIVERING A COPY OF THE PROCESS TO THE PARTY TO BE SERVED AT THE ADDRESS AND IN THE MANNER PROVIDED FOR THE GIVING
OF NOTICES IN SECTION 7.6. NOTHING IN THIS SECTION 7.4, HOWEVER, SHALL AFFECT THE RIGHT OF ANY PARTY TO SERVE LEGAL
PROCESS IN ANY OTHER MANNER PERMITTED BY LAW.


 




    	[Confidential Treatment Requested]

26



    	 



    

 


7.5 Assignability; No Third Party Beneficiaries.


 


This Agreement shall be
binding upon, and shall be enforceable by and inure solely to the benefit of, the Parties and their respective successors and
assigns. No Party may assign any of its rights or obligations hereunder without the prior written consent of the other Party,
and any attempted assignment or delegation of this Agreement or any of such rights or obligations by such Party without the other
Party’s prior written consent shall be void and of no effect; provided that the Seller may assign its rights to payments
under Section 1.7 of this Agreement to any other Person without the prior written consent of the Buyer or any other Party.
Nothing in this Agreement, express or implied, is intended to or shall confer upon any Person any right, benefit or remedy of
any nature whatsoever under or by reason of this Agreement.


 


7.6 Notices.


 


Any notice or other communication
required or permitted to be delivered to a Party under this Agreement shall be in writing and shall be deemed properly delivered,
given and received when delivered by hand, by registered mail, by courier or express delivery service or by facsimile to the address
or facsimile telephone number set forth beneath the name of such Party below (or to such other address or facsimile telephone
number as such Party shall have specified in a written notice given to the other Parties):


 


if to the Seller:


 


780 Third Avenue

37th Floor

New York, NY 10017

Fax: (212) 573-8111

Attention:     James E. Flynn


David J. Clark


 


with a copy to (which shall not constitute notice):


 


Robinson, Bradshaw & Hinson, P.A.

101 North Tryon Street, Suite 1900

Charlotte, NC 28246

Fax: (704) 339-3428

Attention:   Mark O. Henry


 


if to Flamel, the Buyer or the Company:


 


Flamel Technologies S.A.

Parc Club du Moulin a Vent

33, avenue du Docteur Georges Levy

69693 Venissieux Cedex France

Attention:


 


with a copy to (which shall not constitute notice):


 


Hogan Lovells US LLP

200 International Drive

Baltimore, MD 21202

Facsimile: (410) 659-2701

Attention:   Asher M. Rubin


 




    	[Confidential Treatment Requested]

27



    	 



    



  


William I. Intner


 


and


 


Hogan Lovells US LLP

555 Thirteenth St. NW

Washington, DC 20004

Facsimile: (202) 637-5910

Attention:G. Allen Hicks


 


7.7           Severability.


 


Any term or provision
of this Agreement that is invalid or unenforceable in any situation in any jurisdiction shall not affect the validity or enforceability
of the remaining terms and provisions of this Agreement or the validity or enforceability of the offending term or provision in
any other situation or in any other jurisdiction. If a final judgment of a court of competent jurisdiction declares that any term
or provision of this Agreement is invalid or unenforceable, the Parties agree that the court making such determination shall have
the power to limit such term or provision, to delete specific words or phrases or to replace such term or provision with a term
or provision that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable
term or provision, and this Agreement shall be valid and enforceable as so modified. In the event such court does not exercise
the power granted to it in the prior sentence, the Parties agree to replace such invalid or unenforceable term or provision with
a valid and enforceable term or provision that will achieve, to the extent possible, the economic, business and other purposes
of such invalid or unenforceable term or provision.


 


7.8           Other
Remedies; Specific Performance.


 


Except as otherwise provided
herein, any and all remedies herein expressly conferred upon a Party will be deemed cumulative with and not exclusive of any other
remedy conferred hereby, or by law or equity upon such Party, and the exercise by a Party of any one remedy will not preclude
the exercise of any other remedy. The Parties agree that irreparable damage would occur in the event that any of the provisions
of this Agreement were not performed in accordance with their specific terms or were otherwise breached. It is accordingly agreed
that the Parties shall be entitled to seek an injunction or injunctions to prevent breaches of this Agreement and to enforce specifically
the terms and provisions hereof, this being in addition to any other remedy to which they are entitled at law or in equity.


 


7.9           Noncompete.


 


Effective as of the Effective
Time, the Seller hereby releases Michael S. Anderson from all obligations under the Confidentiality, Non-Solicitation and Non-Competition
Agreement between the Seller and Michael S. Anderson, and acknowledges and agrees such agreement shall be terminated and of no
further force and effect.


 




    	[Confidential Treatment Requested]

28



    	 



    

 


7.10         Judgment
Currency.


 


(a)          If,
for the purpose of obtaining or enforcing judgment against any Party in any court in any jurisdiction with respect to this Agreement
it becomes necessary to convert into any other currency (such other currency being hereinafter referred to as the “Judgment
Currency”) an amount due in United States dollars, the conversion shall be made at the last exchange rate published
in the Wall Street Journal on the business day immediately preceding (the “Exchange Rate”):


 


(i)          the
date actual payment of the amount is due, in the case of any proceeding in the courts of Delaware or in the courts of any other
jurisdiction that will give effect to payment being due on such date; or


 


(ii)         the
date on which the French or any other non U.S. court determines, in the case of any proceeding in the courts of any other jurisdiction
(the date as of which such payment is made being hereinafter referred to as the "Judgment Payment Date").


 


(b)          If
in the case of any proceeding in the court of any jurisdiction referred to above, there is a change in the Exchange Rate on the
date of calculation prevailing between the Judgment Payment Date and the date of actual payment of the amount due, the applicable
Party shall pay such adjusted amount as may be necessary to ensure that the amount paid in the Judgment Currency, when converted
at the Exchange Rate prevailing on the date of payment, will produce the amount of United States dollars which could have been
purchased with the amount of Judgment Currency stipulated in the judgment or judicial order at the Exchange Rate prevailing on
the Judgment Payment Date.


 


(c)          Any
amount due from Buyer under this Section 7.10 shall be due as a separate debt and shall not be affected by judgment being
obtained for any other amount due under or in respect of this Agreement.


 


7.11         Construction.


 


(a)          For
purposes of this Agreement, whenever the context requires: the singular number shall include the plural, and vice versa; and any
gender shall include all genders.


 


(b)          The
Parties agree that any rule of construction to the effect that ambiguities are to be resolved against the drafting Party shall
not be applied in the construction or interpretation of this Agreement.


 


(c) As used
in this Agreement, the words “include” and “including,” and variations thereof, shall not be deemed to
be terms of limitation, but rather shall be deemed to be followed by the words “without limitation.”


 


(d) Except
as otherwise indicated, all references in this Agreement to “Sections,” “Exhibits” and “Schedules”
are intended to refer to Sections of this Agreement and Exhibits and Schedules to this Agreement.


 


(e) The headings
contained in this Agreement are for convenience of reference only, shall not be deemed to be a part of this Agreement and shall
not be referred to in connection with the construction or interpretation of this Agreement.


 


[Remainder of page intentionally left blank;
signature pages follow.]


 




    	[Confidential Treatment Requested]

29



    	 



    

  





IN WITNESS WHEREOF, the Parties have
caused this Agreement to be executed as of the date first above written.


 


	 	ÉCLAT HOLDINGS, LLC
	 	 
	 	By:	/s/ Michael
    S. Anderson
	 	Name: Michael S. Anderson
	 	Title: President & CEO


 


	 	ÉCLAT PHARMACEUTICALS, LLC


 


	 	By:	/s/ Michael
    S. Anderson
	 	Name: Michael S. Anderson
	 	Title: President & CEO


 


	 	FLAMEL TECHNOLOGIES S.A.


 





	 	By:	/s/ Stephen
    H. Willard
	 	Name: Stephen
    H. Willard
	 	Title: Chief
    Executive Officer







 


	 	FLAMEL US HOLDINGS, INC.


 





	 	By:	/s/ Stephen
    H. Willard
	 	Name: Stephen
    H. Willard
	 	Title: President







 


SIGNATURE PAGE TO MEMBERSHIP INTEREST PURCHASE
AGREEMENT




  






    	 



    	 



    

 


EXHIBIT A 


 


CAPITALIZED TERMS


 


For purposes of the Agreement (including this Exhibit A):


 


“Accelerated Earn-Out Value”
shall mean as of any date of determination, the amount of future Launch Products Deferred Payments and Hycet Deferred Payments
that would be paid to Seller using the Buyer’s good faith projections of future sales of the Product and the Launch Products
at the time of the applicable Acceleration Trigger Event, discounted to present value as of the date of the Acceleration Trigger
Event using quarterly compounding and a discount rate of 4%.


 


“Acceleration Trigger Event”
shall mean the occurrence of any one or more of the following events:


 


(a) Flamel or the Company shall (i) file a voluntary
petition or commence a voluntary case seeking liquidation, winding-up, reorganization, dissolution, arrangement, readjustment
of debts or any other relief under the Bankruptcy Code or under any other applicable bankruptcy, insolvency or similar law now
or hereafter in effect, (ii) apply for or consent to the appointment of or taking possession by a custodian, trustee, receiver
or similar official for or of itself or all or a substantial part of its properties or assets, (iii) fail generally, or admit
in writing its inability, to pay its debts generally as they become due, (iv) make a general assignment for the benefit of creditors
or (v) take any corporate action to authorize or approve any of the foregoing; or


 


(b) Any involuntary petition or case shall be filed or
commenced against Flamel or the Company seeking liquidation, winding-up, reorganization, dissolution, arrangement, readjustment
of debts, the appointment of a custodian, trustee, receiver or similar official for it or all or a substantial part of its properties
or any other relief under the Bankruptcy Code or under any other applicable bankruptcy, insolvency or similar law now or hereafter
in effect, and such petition or case shall continue undismissed and unstayed for a period of 60 days; or an order, judgment or
decree approving or ordering any of the foregoing shall be entered in any such proceeding.


 


“Adjusted Working Capital”
shall mean an amount equal to the net book value, determined without duplication in accordance with GAAP as consistently applied
in the same manner as the Financial Statements, of the Company on a consolidated basis of (i) the cash (if any), inventory, accounts
receivable, prepaid assets and other current assets, minus (ii) the accounts payable, accrued current operating liabilities
(including, for purposes of clarification, any necessary accrual for Taxes in accordance with GAAP) and the Return, Rebate and
Chargeback Accrual (excluding, for purposes of clarification, the Company Indebtedness, which is being satisfied pursuant to Section
1.5.)


 


“ANDA” means Abbreviated
New Drug Application numbered 040482, approved September 25, 2003.


 




    	[Confidential Treatment Requested]



    	 



    

 


“Bankruptcy Code”
means 11 U.S.C. §§ 101 et seq., as amended from time to time, and any successor statute, and all regulations from time
to time promulgated thereunder.


 


“Business Day” shall
mean any day other than a day on which banks in New York, NY or Paris, France are authorized or obligated to be closed.


 


“Code” shall mean
the Internal Revenue Code of 1986, as amended.


 


“Company Indebtedness”
means all obligations for borrowed money owed by the Company Parties immediately prior to the Effective Time and any liens on
the assets of the Company Parties securing such obligations.


 


“Company Party” means
each of the Company and all of its Subsidiaries and “Company Parties” means the Company and all of its
Subsidiaries collectively.


 


“Consent” shall mean
any approval, consent, ratification, permission, waiver or authorization (including any Governmental Authorization).


 


“Contract” shall,
with respect to any Person, mean any written, oral or other agreement, contract, subcontract, lease (whether real or personal
property), mortgage, understanding, arrangement, instrument, note, option, warranty, purchase order, license, sublicense, insurance
policy, benefit plan or legally binding commitment or undertaking of any nature to which such Person is a party or by which such
Person or any of its assets are bound or affected under applicable law.


 


“Copyright” means
all copyrights and moral rights, including the legal right provided by the Copyright Act of 1976, as amended, to the expression
contained in any work of authorship fixed in any tangible medium of expression together with any similar rights arising in any
other country as a result of statute or treaty, and all registrations, applications, renewals, extensions and reversions thereof.


 


“DEA” means the United
States Drug Enforcement Administration or any successor agency thereto.


 


“Default Rate” shall
mean 15%.


 


“DGCL” shall mean
the General Corporation Law of the State of Delaware.


 


“Direct Costs” means
the direct costs of acquiring the Product or the Launch Products, as applicable, at the actual contracted cost from a third-party
manufacturer plus the cost of freight to the Company’s distribution center from the third-party manufacturer. In the event
that one or more of the Product, or the Launch Products, as applicable, is manufactured directly by the Buyer, the parties shall
negotiate in good faith to revise the definition of “Direct Costs” to specify the costs to be included, which shall
not include any sales or marketing expenses or any general overhead allocations.


 


“D&O Indemnified Parties”
means each Person who was at any time prior the Effective Time a director or officer of any Company Party.


 




    	[Confidential Treatment Requested]



    	 



    

 


“Earnings Report”
means, (i) during any period when Buyer is obligated to file reports under the provisions of the Securities Exchange Act of 1934,
the Form 6-K filed by Buyer containing its financial information for such quarter and (ii) during any period when Buyer is not
obligated to file reports under the provisions of the Securities Exchange Act of 1934, the internal financial statements prepared
by Buyer.


 


“Encumbrance” shall
mean any lien, pledge, hypothecation, charge, mortgage, security interest, encumbrance, easement, condition, preemptive right,
community property interest, right of first refusal or right of first offer, or similar restriction of any kind, including any
restriction on the voting of any security or Equity Interest, any restriction on the transfer of any security, Equity Interest
or other asset, and any restriction on the receipt of any income or exercise of any other attribute of ownership, under any Legal
Requirement.


 


“Entity” shall mean
any corporation (including any non-profit corporation), partnership (including any general partnership, limited partnership or
limited liability partnership), joint venture, estate, trust, company (including any company limited by shares, limited liability
company or joint stock company), firm, society or other enterprise, association, organization or entity.


 


“Equity Interests”
means, with respect to any Person, the capital stock, limited liability company interests, membership interests, partnership interests
or other equity interests of such Person.


 


“ERISA” shall mean
the Employee Retirement Income Security Act of 1974, as amended.


 


“FDA” means the United
States Food and Drug Administration or any successor agency thereto.


 


“FSC Agreement” means
that certain License and Assignment Agreement dated as of June 23, 2011 by and between Eclat Pharmaceuticals, LLC and FSC Laboratories,
Inc., as amended on the date hereof.


 


“Fundamental Representations”
means those representations and warranties set forth in Sections 2.1 (Organization; Good Standing), 2.2 (Consents
and Approvals; No Violation), 2.3 (Capital Stock; Subsidiaries), 2.18 (Brokers), 3.2 (Authority; Enforceability)
and 3.3 (Consents and Approvals; No Violation).


 


“GAAP” means generally
accepted accounting principles as recognized by the American Institute of Certified Public Accountants.


 


“Governmental Authorization”
shall mean any: (a) permit, license, certificate, franchise, permission, variance, exceptions, orders, clearance, registration,
qualification or authorization issued, granted, given or otherwise made available by or under the authority of any Governmental
Body or pursuant to any Legal Requirement; or (b) right under any Contract with any Governmental Body.


 


“Governmental Body”
shall mean any: (a) nation, state, commonwealth, province, territory, county, municipality, district or other jurisdiction of
any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or quasi-governmental authority
of any nature (including any governmental division, department, agency, commission, instrumentality, official, ministry, fund,
foundation, center, organization, unit, body or Entity and any court or other tribunal, and for the avoidance of doubt, any Taxing
authority); or (d) self regulatory organization (including the NASDAQ Global Market).


 




    	[Confidential Treatment Requested]



    	 



    

 


“Hycet Gross Profit”
means Net Sales of the Product minus Direct Costs of the Product.


 


“IRS” shall mean the
United States Internal Revenue Service.


 


“Know-How” means
ideas, designs, concepts, compilations of information methods, techniques, methodologies, procedures and processes, compositions,
specifications, techniques, technical data and information, designs, drawings, customer lists, supplier lists, pricing and financial
information, plans and proposals, algorithms and formulas, whether or not patentable.


 


“Knowledge” means,
with respect to an individual, that such individual is actually aware of the relevant fact. “Knowledge of the Company”
means the actual knowledge of Michael S. Anderson, Chris Keith, Laurie Fendler or Scott Macke.


 


“Launch Products”
shall mean Neostigmine Methylsulfate Injection, Phenylephrine HCl Injection, [***].


 


“Launch Products Gross Profit”
means Net Sales of the Launch Products minus Direct Costs of the Launch Products.


 


“Legal Proceeding”
shall mean any action, suit, litigation, arbitration, proceeding (including any civil, criminal, administrative, investigative
or appellate proceeding), hearing, inquiry, audit, examination or investigation commenced, brought, conducted or heard by or before,
or otherwise involving, any court or other Governmental Body or any arbitrator or arbitration panel, whether at law or in equity.


 


“Legal Requirement”
shall mean any federal, state, foreign, local or municipal or other law, statute, constitution, principle of common law, resolution,
ordinance, code, edict, decree, rule, regulation, judgment, ruling or requirement issued, enacted, adopted, promulgated, implemented
or otherwise put into effect by or under the authority of any Governmental Body.


 


“Mark” means any
word, name, symbol, logos or device used by a Person to identify its goods or services, whether or not registered, all goodwill
associated therewith, and any right that may exist to obtain a registration with respect thereto from any Governmental Authority
and any rights arising under any such application, together with all registrations, renewals, extensions and reversions thereof.
As used in this Agreement, the term “Mark” includes all of the foregoing, including trademarks and service
marks.


 


[***] Confidential treatment requested for deleted portion.


 




    	[Confidential Treatment Requested]



    	 



    

 


“Net Sales” shall
mean, without duplication, the gross amount invoiced by or on behalf of the Buyer, the Company Parties or any of their Affiliates
or any direct or indirect assignee or licensee of the Buyer or the Company Parties or any of their Affiliates for Product, or
the Launch Products, as applicable, sold globally in bona fide, arm’s length transactions, less customary deductions
determined without duplication in accordance with the selling Person’s customary accounting methods as generally and consistently
applied for: (i) cash or terms discounts, (ii) sales, use and value added taxes (if and only to the extent included in the gross
invoice amount), (iii) reasonable and customary accruals for third party rebates and chargebacks, (iv) returns and (v) recalls.


 


“Ordinary Course of Business”
shall mean, in the case of each of the Company and its Subsidiaries, such actions taken in the ordinary course of its normal operations
and consistent with its past practices.


 


“Ordinary Shares”
means the Ordinary Shares with a nominal value 0.122 Euros per share of Flamel.


 


“Party” or “Parties”
shall mean the Buyer and the Seller.


 


“Patent” means any
patent granted by the United States Patent and Trademark Office or by the comparable agency of any other country, and any renewal,
thereof, and any rights arising under any patent application filed with the United States Patent and Trademark Office or the comparable
agency of any other country and any rights that may exist to file any such application, including all continuations, divisional,
continuations-in-part and provisionals and patents issuing thereon, and all reissues, reexaminations, substitutions, renewals
and extensions thereof.


 


“Permitted Encumbrances”
means (a) statutory liens for Taxes that are not yet due and payable or Taxes that are being contested in good faith by appropriate
proceedings; (b) statutory, common law or civil law liens to secure obligations to landlords, lessors or renters under leases
or rental agreements confined to the premises rented pursuant to which the applicable Company Party is not in default in any material
respect, and which are not, individually or in the aggregate, material to the business of the Company; (c) deposits or pledges
made in connection with, or to secure payment of, workers’ compensation, unemployment insurance, old age pension or other
social security programs mandated under Legal Requirements, which are not, individually or in the aggregate, material to the business
of the Company; (d) statutory, common or civil law liens in favor of carriers, warehousemen, mechanics and materialmen to secure
claims for labor, materials or supplies and other like liens with respect to amounts not yet due and payable, which are not, individually
or in the aggregate, material to the business of the Company.


 


“Person” shall mean
any individual, Entity or Governmental Body.


 


“Product” means the
drug product sold under the ANDA containing hydrocodone bitartrate 7.5 mg and acetaminophen 325 mg (per 15 ml) in liquid form
for oral administration.


 


“Product Intellectual Property”
shall mean all Proprietary Rights held or licensed by the Company Parties that is, or may hereafter be, necessary to develop,
make, have made, promote, market or sell the Product and the Launch Products in the United States.


 




    	[Confidential Treatment Requested]



    	 



    

 


“Product Regulatory Rights”
shall mean each and every investigational new drug application or new drug application and/or state license or registration that
is held or obtained (if any) that is necessary to develop, conduct clinical trials relating to, manufacture, have manufactured,
distribute, promote, market or sell the Product and each Launch Product in the United States of America.


 


“Proprietary Rights”
means, with respect to a Person, all Copyrights, Marks, Trade Names, Trade Secrets, Patents, intellectual property rights in inventions
and discoveries, intellectual property rights in internet web sites and internet domain names and subdomain names and intellectual
property rights in Know-How, owned or used by such Person.


 


“Representatives”
shall mean directors, officers, other employees, agents, attorneys, accountants, advisors and representatives.


 


“Return, Rebate and Chargeback
Accrual” shall mean the estimated liabilities of the Company Parties as of the Closing Date for returns, rebates,
chargebacks and other similar liabilities.


 


An Entity shall be deemed to be a “Subsidiary”
of another Person if such Person directly or indirectly owns or purports to own, beneficially or of record, (a) an amount of voting
securities of other interests in such Entity that is sufficient to enable such Person to elect at least a majority of the members
of such Entity’s board of directors or other governing body, or (b) at least 50% of the outstanding equity, voting, beneficial
or financial interests in such Entity.


 


“Tax” shall mean
any federal, state, local, foreign or other taxes, levies, charges and fees or other similar assessments or liabilities in the
nature of a tax, including, without limitation, any income tax, franchise tax, capital gains tax, gross receipts tax, value-added
tax, surtax, estimated tax, unemployment tax, national health insurance tax, excise tax, ad valorem tax, transfer tax, stamp tax,
sales tax, use tax, property tax, business tax, withholding tax, payroll tax, customs duty, alternative or add-on minimum or other
tax of any kind whatsoever, and including any fine, penalty, assessment, addition to tax or interest, whether disputed or not.


 


“Tax Return” shall
mean any return (including any information return), report, statement, declaration, estimate, schedule, notice, notification,
form, election, certificate or other document or information, and any amendment or supplement to any of the foregoing, filed with
or submitted to, or required to be filed with or submitted to, any Governmental Body in connection with the determination, assessment,
collection or payment of any Tax or in connection with the administration, implementation or enforcement of or compliance with
any Legal Requirement relating to any Tax.


 


“Trade Names” means
any words, name or symbol used by a Person to identify its business.


 


“Trade Secrets” means
business or technical information of any Person including, but not limited to, customer lists, marketing data and Know-How, that
is not generally known to other Persons who are not subject to an obligation of nondisclosure and that derives actual or potential
commercial value from not being generally known to other Persons.




    	[Confidential Treatment Requested]



    	 



    

 


ADDITIONAL DEFINITIONS 


 


Each of the following definitions is set forth
in the section of the Agreement indicated below:


 


	Definition	 	Section
	Adjusted Working Capital Statement 	 	1.3(b) 
	Agreement	 	Preamble
	Audit Notice	 	1.7(d)
	Balance Sheet	 	2.4
	Balance Sheet Date	 	2.4
	Buyer 	 	Preamble
	Buyer Documents	 	4.2
	Closing	 	1.6(a)
	Closing Balance Sheet	 	1.3(b)
	Closing Date	 	1.6(a)
	Company	 	Recitals
	Company Transaction Payments	 	2.22
	Disclosure Schedule	 	2
	Deferred Payment Calculation	 	1.7(b)
	Deferred Payment Calculation Objection Notice	 	1.7(d)
	Effective Time	 	1.6(a)
	Estimated Adjusted Working Capital	 	1.3(a)
	Financial Statements	 	2.4
	Flamel	 	Preamble
	Foreign Plan	 	2.9(d)
	Hycet Product Deferred Consideration	 	1.7(a)
	Hycet Product Deferred Payment	 	1.7(a)
	Launch Products Deferred Consideration	 	1.7(a)
	Launch Products Deferred Payment	 	1.7(a)
	Leased Real Property	 	2.11
	Loan Agreement	 	1.2(a)
	Material Contract	 	2.17(a)
	Note	 	1.2(a)
	Pension Plan	 	2.9(d)
	Product Suppliers	 	2.16
	Reviewing Accountant	 	1.3(e)
	Seller Preamble Seller Documents	 	3.2
	Units Recitals Warrant Agreement 	 	1.2(b)
	Warrant Consideration	 	1.2(b)
	Working Capital Objection Notice	 	1.3(d) 


 




    	[Confidential Treatment Requested]



    	 



    

 


DISCLOSURE SCHEDULES
TO THE


 


MEMBERSHIP INTEREST PURCHASE
AGREEMENT


 


by and among


 


ÉCLAT HOLDINGS,
LLC,


 


a Delaware limited liability
company;


 


ÉCLAT PHARMACEUTICALS,
LLC,


 


a Delaware limited liability
company;


 


FLAMEL TECHNOLOGIES,
SA,


 


a société
anonyme organized under the laws of the Republic of France; and


 


FLAMEL US HOLDINGS, INC.,


 


a Delaware corporation.
Dated as of March 13, 2012


 


Capitalized terms used in these Disclosure Schedules that are not
otherwise defined herein shall have the respective meanings ascribed to them in the Membership Interest Purchase Agreement referred
to above.


 




    	[Confidential Treatment Requested]



    	 



    

Schedule 1.3(a) 


 


Estimated Adjusted Working Capital


 


	Cash	 	$	1,629,502	 
	 	 	 	 	 
	Inventory	 	$	35,551	 
	 	 	 	 	 
	Accounts Receivable	 	$	262,524	 
	 	 	 	 	 
	Prepaid Assets	 	$	433,466	 
	 	 	 	 	 
	Other Current Assets	 	$	14,713	 
	 	 	 	 	 
	Total	 	$	2,375,756	 
	 	 	 	 	 
	Accounts Payable	 	$	235,617	 
	 	 	 	 	 
	Accrued Operating Liabilities	 	$	98,968	 
	 	 	 	 	 
	Return Rebate and Chargeback	 	$	40,000	 
	 	 	 	 	 
	Total	 	$	374,585	 
	 	 	 	 	 
	Adjusted Working Capital	 	$	2,001,171	 



 




    	[Confidential Treatment Requested]



    	 



    

 


Schedule 1.8 


 


Warrant Consideration


 


2.2mm struck at $7.44


1.1mm struck at $11.00


 


Aggregate Black Scholes Valuation is $3,884,210.


 




    	[Confidential Treatment Requested]



    	 



    

 


Schedule 2.1 


 


Jurisdiction/Directors/Officers


 


Éclat Pharmaceuticals, LLC and Talec Pharma, LLC are registered
to do business in Missouri, Montana, North Dakota, and Maine as foreign limited liability companies.


 


Éclat Pharmaceuticals, LLC Manager and Officers


 


Manager:


Éclat Holdings, LLC


 


Officers:


		·	Mike
                                         Anderson (President & CEO) 



		·	Chris
                                         Keith (Vice President) 



		·	Alex
                                         Karnal (Secretary) 



 


Talec Pharma, LLC Manager and Officers


 


Manager:


Éclat Pharmaceuticals, LLC


 


Officers:


		·	Mike
                                         Anderson (President & CEO) 



		·	Chris
                                         Keith (Vice President)



		·	Alex
                                         Karnal (Secretary) 



 




    	[Confidential Treatment Requested]



    	 



    

 


Schedule 2.2 


 


Consents and Approvals


 


The following agreements require consent upon
the consummation of the transactions contemplated by the Agreement:


 


License and Assignment Agreement, dated as
of June 23, 2011 between Éclat Pharmaceuticals, LLC and FSC Laboratories, Inc.


 


Wholesale Purchase Agreement, dated as of
June 20, 2011, between Cardinal Health and Éclat Pharmaceuticals, LLC


 


Developing Suppliers Program Distribution
Services Agreement, effective July 15, 2011, between Cardinal Health and Éclat Pharmaceuticals, LLC.


 




    	[Confidential Treatment Requested]



    	 



    

 


Schedule 2.4 Financial Statements See attached.



 




    	[Confidential Treatment Requested]



    	 



    

 





Consolidated


December 31, 2011 and 2010


 





	Income Statement	 	2011	 	 	2010	 
	Net revenue	 	$	608,777	 	 	$		 
	Cost of goods	 	 	303,697	 	 	 	—	 
	Gross profit	 	 	305,080	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	General and administration	 	$	1,751,135	 	 	$	141,033	 
	Selling and marketing	 	 	622,006	 	 	 	29,038	 
	Research and development	 	 	1,486,756	 	 	 	75,000	 
	Total expense	 	 	3,859,898	 	 	 	245,071	 
	Net loss	 	$	(3,554,818	)	 	$	(245,071	)



 


	Balance Sheet	 	 	2011	 	 	 	2010	 
	Cash	 	$	4,104,329	 	 	$	1,712,309	 
	Accounts receivable	 	 	184,114	 	 	 	—	 
	Inventory	 	 	52,285	 	 	 	-	 
	Prepaid	 	 	341,342	 	 	 	24,693	 
	Other current assets	 	 	3,367	 	 	 	-	 
	Property	 	 	59,862	 	 	 	52,268	 
	Intangibles	 	 	3,621,429	 	 	 	-	 
	Deposits	 	 	5,426	 	 	 	12,926	 
	 	 	 	8,372,154	 	 	 	1,802,196	 
	Total assets	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	Accounts payable	 	 	204,472	 	 	 	18,415	 
	Accrued liabilities	 	 	111,017	 	 	 	27,722	 
	Other short-term	 	 	750,000	 	 	 	-	 
	liabilities Long-term debt	 	 	6,000,000	 	 	 	-	 
	Other long-term liabilities	 	 	2,106,554	 	 	 	1,130	 
	 	 	 	9,172,043	 	 	 	47,267	 
	Total liabilities	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	Capital accounts	 	 	3,000,000	 	 	 	2,000,000	 
	Retained deficit	 	 	(245,071	)	 	 	—	 
	Net loss	 	 	(3,554,818	)	 	 	(245,071	)
	 	 	 	 	 	 	 	 	 
	Total capital	 	 	(799,889	)	 	 	1,754,929	 
	 	 	 	 	 	 	 	 	 
	Total liabilities and capital	 	$	8,372,154	 	 	$	1,802,196	 





  




    	[Confidential Treatment Requested]



    	 



    

 


Schedule 2.5




 


Absence of Changes


 


Éclat Pharmaceuticals, LLC amended and restated its Limited
Liability Company agreement, effective March 13, 2012.


 




    	[Confidential Treatment Requested]



    	 



    

 


Schedule 2.6(a)


 


Tax Matters


 


None


 




    	[Confidential Treatment Requested]



    	 



    

 


Schedule 2.9(c) 


 


Independent Contractors


 


Michael J. Murray, M.D., Ph.D., via a Consulting Agreement, between
Michael J. Murray, M.D., Ph.D. and Éclat Pharmaceuticals, LLC, dated April 8, 2011.


 


Diana Rogers, via a Consulting Agreement, between Diana Rogers
and Éclat Pharmaceuticals, LLC, dated May 1, 2011.


 




    	[Confidential Treatment Requested]



    	 



    

 


Schedule 2.10 


 


Insurance


Property/Automobile/Inland Marine


 


		·	Carrier-
                                         Acuity 



		·	Effective
                                         Date- 12/10/2011 



		·	Coverage
                                         Amount- $120,000 



 


Employment Practices Liability


 


		·	Carrier-
                                         XL Insurance 



		·	Effective
                                         Date- 12/10/2011 



		·	Coverage
                                         Amount- $1,000,000 



 


Workers Compensation


 


		·	Carrier-
                                         Travelers 



		·	Effective
                                         Date- 12/10/2011 



		·	Coverage
                                         Amount- $1,000,000 



 


General Liability, including Products/Completed Operations


 


		·	Carrier-
                                         Evanston Insurance 



		·	Effective
                                         Date- 6/16/2011 



		·	Coverage
                                         Amount- $5,000,000 





    	[Confidential Treatment Requested]



    	 



    

 


Schedule 2.11 


 


Leased Real Property


 


Lease, with a commencement date of November
1, 2010, between Spirit Center Three, LLC and Éclat Pharmaceuticals, LLC for the lease of the building known as 699 Trade
Center Boulevard, Chesterfield, Missouri, 63005.


 




    	[Confidential Treatment Requested]



    	 



    

 


Schedule 2.12 


 


Bank Accounts


 


Accounts with Commerce Bank, N.A.:


 


1) Éclat Pharmaceuticals, LLC Commercial Checking-
acct. #0316917845


 


2) Business Money Market Account- acct. #0316917860


 


3) Talec Pharma, LLC Commercial Checking- acct. #0316918068.


 


Michael Anderson and Laurie Fendler are authorized
signatories for each of the bank accounts reference above.


 




    	[Confidential Treatment Requested]



    	 



    

 


Schedule 2.15(a) 


 


Proprietary Rights


Domain Names:


 


www.eclatpharmaceutical.com Expiration Date: 1/18/2013


 


www.TALECPHARMA.COM Expiration Date: 5/2/2012


 


www.TALECPHARMACEUT ICAL.COM Expiration Date: 5/2/2012


 


www.TALECPHARMACEUTICALS.COM Expiration Date: 5/2/2012


 


www.ECLATPHARMA.COM Expiration Date: 12/2/2013


 


www.ECLATPHARMACEUT ICALS.COM Expiration
Date:12/2/2013


 


www.Hycet.com Expiration Date: 12/19/2015


 


Trademark:


 


HYCET®, U.S. Registration Number 3,012,6561



 





 






1 Pursuant to the License and Assignment Agreement,
dated as of June 23, 2011 between Éclat Pharmaceuticals, LLC and FSC Laboratories, Inc., Éclat Pharmaceuticals is
required to pay a fee for the use of this trademark.


 




    	[Confidential Treatment Requested]



    	 



    

 


Schedule 2.17(a) 


 


Material Contracts


 


(i)


 


		·	Manufacturing
                                         and Supply Agreement between Éclat Pharmaceuticals, LLC and Mikart, LLC, dated
                                         June 27, 2011. 



		·	Product
                                         Promotion Agreement, dated June 23, 2011, between FSC Pediatrics, Inc. and Éclat
                                         Pharmaceuticals, LLC 



		·	Prosar
                                         Agreement, dated May 23, 2011, between Product Safety Resources, Inc. and Éclat
                                         Pharmaceuticals, LLC. 



		·	Consultancy
                                         and Services Agreement, dated June 24, 2011 between Beckloff Associates, Inc. and Éclat
                                         Pharmaceuticals, LLC. 



		·	Information
                                         Services Agreement, between IMS Health Incorporated and Éclat Pharmaceuticals,
                                         LLC, dated February 1, 2011. 



		·	Phenylephrine
                                         HCL Injection Process Development Pricing Proposal, dated as of June 3, 2011, between
                                         Patheon UK Limited and Éclat Pharmaceuticals, LLC, as supplemented by change of
                                         scope documentation. 



		·	[***]
                                         Pricing Proposal, dated November 26, 2011, between Pantheon UK Limited and Éclat
                                         Pharmaceuticals, LLC, as supplemented by change of scope documentation. 



		·	Neostigmine
                                         Methlysulfate Injection Formulation Development Pricing Proposal, between Pantheon UK
                                         Limited and Éclat Pharmaceuticals, LLC, dated as of February 21, 2011. 



		·	Generic
                                         Wholesale Service Agreement, dated August 1, 2011 between Cardinal Health and Talec Pharma,
                                         LLC. 



		·	Developing
                                         Suppliers Program Distribution Services Agreement, effective July15, 2011, between Cardinal
                                         Health and Éclat Pharmaceuticals, LLC. 



		·	Service
                                         Agreement, dated April 20, 2011, between Talec Pharmaceuticals, LLC and DDN/OBERGFEL,
                                         LLC, as amended. 



		·	Service
                                         Agreement, dated February 14, 2011, between Éclat Pharmaceuticals, LLC and DDN/OBERGFEL,
                                         LLC, as amended. 



		·	Data
                                         Services Agreement, dated as of June 6, 2011, between Éclat Pharmaceuticals and
                                         H.D. Smith Wholesale Drug Co. 



		·	Distribution
                                         Services Agreement, dated as of June 14, 2011, between Amerisource Bergen Drug Corporation,
                                         Éclat Pharmaceuticals and Bellco Drug Corp. 



		·	Letter
                                         Agreement, between Éclat Pharmaceutical Company and The Weinberg Group, dated
                                         October 20, 2010. 



		·	Letter
                                         Agreement between Éclat Pharmaceutical Company, LLC and The Weinberg Group, dated
                                         September 3, 2010. 



		·	Letter
                                         Agreement between Éclat Pharmaceuticals and The Weinberg Group, dated May 18,
                                         2011. 



 


[***] Confidential treatment requested for deleted portion.


 




    	[Confidential Treatment Requested]



    	 



    

 


		·	Agreement
                                         on Audit Execution, between Éclat Pharmaceuticals and Boehringer Ingelheim Pharma
                                         GmbH & Co. KG, dated September 30, 2011. 



		·	Consulting
                                         Agreement, dated February 7, 2011 between Éclat Pharmaceuticals and Compliance
                                         Insight, Inc. 



		·	Wholesale
                                         Purchase Agreement, dated as of June 20, 2011, between CardinalHealth and Éclat
                                         Pharmaceuticals, LLC. 



		·	Sample
                                         Fulfillment Agreement, dated as November 30, 2011, between Éclat Pharmaceuticals,
                                         LLC and Foundation Care, LLC. 



 


(ii)


 








		·	License
                                         and Assignment Agreement, dated as of June 23, 2011, between Éclat Pharmaceuticals,
                                         LLC and FSC Laboratories, Inc. 



		·	Manufacturing
                                         and Supply Agreement between Éclat Pharmaceuticals, LLC and Mikart, LLC, dated
                                         June 27, 2011. 



		·	Standard
                                         License Agreement, effective as of January 1, 2011, between First Databank, Inc. and
                                         Éclat Pharmaceuticals, LLC 








 


(iii)


 


		·	Lease,
                                         with a commencement date of November 1, 2010, between Spirit CenterThree, LLC and Éclat
                                         Pharmaceuticals, LLC for the lease of the building known as 699 Trade Center Boulevard,
                                         Chesterfield, Missouri, 63005. 



 


(iv)


 


		·	Limited
                                         Liability Company Agreement of Éclat Pharmaceuticals, LLC, effective October 18,
                                         2010, between Éclat Holdings, LLC and Éclat Pharmaceuticals, LLC. 



		·	Limited
                                         Liability Company Agreement of Talec Pharma, LLC, effective as of April 5, 2011, between
                                         Éclat Pharmaceuticals, LLC and Talec Pharma, LLC. 



 


(v) None.


 


(vi) None.


 


(vii)


 


		·	Irrevocable
                                         Standby Letter of Credit for Maryland Board of Pharmacy, issued 6/27/2011 by Commerce
                                         Bank, N.A. on behalf of Éclat Pharmaceuticals, LLC. 



		·	Note
                                         Purchase Agreement among Éclat Pharmaceuticals, LLC and the investors named therein,
                                         dated as November 1, 2010, along with the promissory notes evidencing the indebtedness
                                         thereunder. 



 


(viii) None.


 




    	[Confidential Treatment Requested]



    	 



    

 


(ix)


 





		·	Pharmaceutical
                                         Pricing Agreement, dated October 28, 2011, between the Secretary of Health and Human
                                         Services and Talec Pharma, LLC. 



		·	Pharmaceutical
                                         Pricing Agreement, dated October 28, 2011, between the Secretary of Health and Human
                                         Services and Éclat Pharmaceuticals, LLC. 





 


(x)


 


		·	Distribution
                                         Services Agreement, dated as of June 14, 2011, between AmerisourceBergenDrug Corporation,
                                         Éclat Pharmaceuticals and Bellco Drug Corp. 



		·	Manufacturing
                                         and Supply Agreement between Éclat Pharmaceuticals, LLC and Mikart, LLC, dated
                                         June 27, 2011. 



		·	Consultancy
                                         and Services Agreement, dated June 24, 2011 between Beckloff Associates, Inc. and Éclat
                                         Pharmaceuticals, LLC 



		·	Phenylephrine
                                         HCL Injection Process Development Pricing Proposal, dated as of June 3, 2011, between
                                         Patheon UK Limited and Éclat Pharmaceuticals, LLC, as supplemented by change of
                                         scope documentation. 



		·	[***]
                                         Pricing Proposal, dated November 26, 2011, between Pantheon UKLimited and Éclat
                                         Pharmaceuticals, LLC, as supplemented by change of scope documentation. 



		·	Neostigmine
                                         Methlysulfate Injection Formulation Development Pricing Proposal, between Pantheon UK
                                         Limited and Éclat Pharmaceuticals, LLC, dated as of February 21, 2011. 



		·	Core
                                         Distribution Agreement, between McKesson Corporation and Éclat Pharmaceuticals,
                                         LLC, dated June 1, 2011, as amended. 



		·	Generic
                                         Wholesale Service Agreement, dated August 1, 2011 between Cardinal Health and Talec Pharma,
                                         LLC. 



		·	Supplier
                                         Agreement (Multisource and Onestop Generic Program), dated as August 1, 2011, between
                                         McKesson Corporation and Talec Pharmaceuticals, LLC. 



		·	Pharmaceutical
                                         Pricing Agreement, dated October 28, 2011, between the Secretary of Health and Human
                                         Services and Talec Pharma, LLC. 



		·	Pharmaceutical
                                         Pricing Agreement, dated October 28, 2011, between the Secretary of Health and Human
                                         Services and Éclat Pharmaceuticals, LLC. 



 


[***] Confidential treatment requested for deleted portion.


 




    	[Confidential Treatment Requested]